U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C.  20549
                   __________________________________________
                                   FORM 10-KSB
(Mark  one)
[X]  Annual  report  under section 13 or 15(d) of the Securities Exchange Act of
     1934
                  For the fiscal year ended September 30, 2001
                                       OR
[ ]  Transition report under section 13 or 15(d) of the Securities Exchange Act
     of  1934
           For the transition Period from ________________ to _________________

                    Commission file number:           0-30096
                                           ------------------

                                 Duro Enzyme Products Inc.
                           -------------------------------
                 (Name of small business issuer in its charter)

                   NEVADA                                 77-0454933
                   ------                                -------------
        (State or other jurisdiction of                 (I.R.S. Employer
        incorporation or organization)                  Identification No.)

                      20436 Fraser Highway
                    Langley, British Columbia               V3A 4G2
                    -------------------------               -------
             (Address of principal executive offices)     (Zip Code)

                   Issuer's telephone number: (604) 888 - 6797
            435 Martin Street, Suite 3000, Blaine, Washington, 98320
          ------------------------------------------------------------
         (Former name of former address, if changed since last report.)

Securities  registered  under  Section  12(b)  of  the  Act:

     (Title  of  Class)                     Name of exchange on which registered
           None                                             None
---------------------------------      -----------------------------------------

----

Securities  registered  under  Section  12(g)  of  the  Act:       Common Stock,
                                                                   -------------
$0.001  par  value
------------------
(Title  of  class)

Check  whether  the Issuer (1) filed all reports required to be filed by Section
13  or  15(d)  of  the Securities Exchange Act during the past 12 months (or for
such  shorter period that the registrant was required to file such reports), and
(2)  has  been  subject to such filing requirements for the past 90 days. Yes X
                                                                             ---
No
   ---
Check  if there is no disclosure of delinquent filers in response to Item 405 of
Regulation  S-B  is  not  contained  in  this  form,  and  no disclosure will be
contained,  to  the  best  of  registrant's  knowledge,  in  definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or  any  amendment  to  this  Form  10-KSB.  [ ]

Registrant's  revenues  for  its  most  recent  fiscal  year:  $Nil
                                                               ----

As  of November 30, 2001, the aggregate market value of the voting common equity
held  by  non-affiliates of the registrant was $64,805,702, based on the closing
trade  reported  on  the NASD Over-the-Counter Bulletin Board National Quotation
System.  Shares  of  common  stock held by each officer and director and by each
person  who  owns five percent or more of the outstanding common stock have been
excluded  from  this  calculation  as  such  persons  may  be  considered  to be
affiliated  with  the  Company.

On  November  30,  2001,  the  registrant had 32,876,400 shares of Common Stock,
$0.001  par  value  per  share,  issued  and  outstanding.

Documents  incorporated  by  reference:  None.

TRANSITIONAL  SMALL  BUSINESS  DISCLOSURE  FORMAT:  Yes  [ ]   No  [X]


<PAGE>
<TABLE>
<CAPTION>
                                      DURO ENZYME PRODUCTS INC.

                                              INDEX TO
                                    ANNUAL REPORT ON FORM 10-KSB
                                FOR THE YEAR ENDED SEPTEMBER 30, 2001


PART I                                                                                          PAGE
<S>                                                                                             <C>
Item 1    Description of Business. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     3
Item 2    Description of Property. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     8
Item 3    Legal Proceedings. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     8
Item 4    Submission of Matters to a Vote of Security Holders. . . . . . . . . . . . . . . . .     9

PART II
Item 5    Market for Common Equity and Related Stockholder Matters . . . . . . . . . . . . . .    10
Item 6    Management's Discussion and Analysis of Financial Condition or Plan of Operations. .    10
Item 7    Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    16
Item 8    Changes In and Disagreements With Accountants on Accounting and Financial Disclosure    16

PART III
Item 9    Directors, Executive Officers, Promoters and Control Persons; Compliance With
          Section 16(a) of the Exchange Act. . . . . . . . . . . . . . . . . . . . . . . . . .    17
Item 10   Executive Compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    18
Item 11   Security Ownership of Certain Beneficial Owners and Management . . . . . . . . . . .    19
Item 12   Certain Relationships and Related Transactions . . . . . . . . . . . . . . . . . . .    19
Item 13   Exhibits and Reports on Form 8-K . . . . . . . . . . . . . . . . . . . . . . . . . .    21

SIGNATURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   .22

FINANCIAL STATEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   .23
</TABLE>


                                        2
<PAGE>
                                     PART I

                           FORWARD-LOOKING STATEMENTS
                           ---------------------------

Except  for  the  historical information presented in this document, the matters
discussed  in  this  Form  10-KSB,  and  specifically  in the sections entitled,
"Description of Business" and "Management's Discussion and Analysis of Financial
Condition  or  Plan  of  Operation," or otherwise incorporated by reference into
this  document  contain "forward-looking statements" (as such term is defined in
the  Private  Securities Litigation Reform Act of 1995). These statements can be
identified  by  the  use  of  forward-looking  terminology  such  as "believes",
"expects",  "may",  "will",  "intends",  "should",  or  "anticipates"  or  the
negative  thereof  or  other variations thereon or comparable terminology, or by
discussions  of  strategy  that involve risks and uncertainties. The safe harbor
provisions  of  Section  21B of the Securities Exchange Act of 1934, as amended,
and  Section  27A  of  the  Securities  Act  of  1933,  as  amended,  apply  to
forward-looking  statements  made  by the Registrant. You should not place undue
reliance on forward-looking statements. Forward-looking statements involve risks
and  uncertainties,  including  those  identified  within  the  section entitled
"Outlook:  Issues  and  Uncertainties"  and  elsewhere  in,  or  incorporated by
reference  into,  this  Form  10-KSB.  The  actual  results  that the Registrant
achieves  may  differ materially from any forward-looking statements due to such
risks  and  uncertainties. These forward-looking statements are based on current
expectations,  and  the  Registrant  assumes  no  obligation  to  update  this
information.  Readers  are  urged  to  carefully review and consider the various
disclosures  made  by the Registrant in this Annual Report on Form 10-KSB and in
the Registrant's other reports filed with the Securities and Exchange Commission
that  attempt  to  advise  interested  parties of the risks and factors that may
affect  the  Registrant's  business.

ITEM  1.  DESCRIPTION  OF  BUSINESS
------------------------------------

CORPORATE  BACKGROUND

Duro  Enzyme  Products  Inc.  (formerly  -  Home.Web, Inc.) (the "Company") is a
Nevada corporation incorporated on September 15, 1995. Since 1997, the Company's
business  plan  consisted  of  organizing  a  gourmet  food and specialty cheese
business  over  the  Internet.

On October 16, 2000, the Company conducted a voluntary share exchange whereby it
offered  up to 28,800,000 shares of its common stock to the shareholders of Duro
Enzyme  Products  Inc., a private Nevada corporation formed on November 29, 1999
("Duro  Enzymes  Private"),  in  exchange  for all of the issued and outstanding
shares  of  Duro  Enzymes  Private.  The  effect  of  the share exchange was the
transfer  of control of the Company to the shareholders of Duro Enzymes Private.
Consequently,  the  majority  of  shares  of  the Company are now held by former
shareholders  of  Duro  Enzymes  Private.  At  this  point, Duro Enzymes Private
merged  with and into the Company and changed the focus of its business from the
distribution  and sale of gourmet foods and specialty cheeses over the Internet,
to  the  business  of  Duro  Enzymes  Private,  involving the use of proprietary
technologies  to  produce  natural  and  stable  enzymes,  and  the research and
development  of  various  applications  for  them.  Following  approval  by  the
Company's  shareholders  at  a special shareholders' meeting held on February 5,
2001,  the  Company's  name was formally changed to Duro Enzyme Products Inc. In
connection  with  the  change  in business, new directors and executive officers
were  appointed.

The  Company's principal executive offices are at 20436 Fraser Highway, Langley,
British  Columbia,  V3A  4G2,  Canada.

PLANNED  FUTURE  OPERATIONS
---------------------------

TECHNOLOGY  LICENSE
-------------------

On  September 21, 2000, 529473 B.C. Ltd., a private British Columbia corporation
(the  licensor)  and  Duro  Solutions,  a  Nevada  corporation  and wholly-owned
subsidiary  of  the  Company,  entered into a License and Distribution Agreement
(the  "License  Agreement"),  which granted to Duro Solutions (the licensee) the
exclusive  right  to use 529473 B.C. Ltd.'s proprietary stable enzyme production
technologies  anywhere  in  the  world.  Through  the  application  of  these
technologies,  Duro  Solutions  has  the  ability to manufacture unique, stable,
natural  enzymes that have a wide range of applications in biological processes.
Under  the  terms  of the License Agreement, Duro Solutions is to pursue further
research  and  development  of  the  proprietary  technologies,  and  market and
distribute  the  resulting  stable enzymes. The License Agreement also grants to
Duro  Solutions  the  right  to sublicense the use of the enzyme technologies in
connection  with  owning  and  operating  a  stable  enzyme  manufacturing  and
production  facility.


                                        3
<PAGE>
Under  the  terms  of the License Agreement, the Company has made a US$2,500,000
promissory  note  bearing interest at a rate of 5% per annum over a period of 10
years  payable  to  529473  B.C.  Ltd.  The  obligation  to make payments on the
promissory  note  does  not  commence  until  the  Company begins selling stable
enzymes.  At  that  time,  the  Company is obligated to pay the entire principal
amount  and  any  accrued interest within five years.  Interest will continue to
accrue  throughout  the  term  of  the note.  In addition, the Company must make
royalty  payments  equal  to 2.5% of gross revenue generated by the Company from
use  of  the  licensed  technologies.  The  royalty payments are to be made on a
quarterly basis. Any further developments of the technologies by the Company are
to  be owned by 529473 B.C. Ltd. and licensed to Duro Solutions.  Duro Solutions
must  assist  529473  B.C.  Ltd.  with  protection  of its intellectual property
through  patent  applications  and  trademark  registrations.

The  License  Agreement  terminates  if either party fails to perform a material
obligation  under  the Agreement for a period of 30 days after receipt of notice
by  the  defaulting  party  from  the  other  party.  In such a case, all legal,
beneficial  and proprietary rights, title and interest in and to the technology,
plans,  know  how,  any research and development work, including all information
and documentation relating thereto, will remain the sole property of 529473 B.C.
Ltd.  Duro  Solutions  will  own any other basic knowledge or technology used in
any research or development.  Duro Solutions will be obligated to provide 529473
B.C.  Ltd.  with  complete  information  concerning  all  sublicense  agreements
executed  prior  to  termination.  Any  dispute  between  the  parties  is to be
referred  to  an  arbitrator  for  resolution.

The Company is party to Research and Development Services Agreements with 529473
B.C.  Ltd.  Under  the terms of the Agreements, the Company and its subsidiaries
have  agreed  to  retain  the  services of 529473 B.C. Ltd. to provide research,
development,  design, and related consultations. 529473 B.C. Ltd. will receive a
consulting  fee  at  a  standard  rate, established by the consultants, and will
charge  an  additional  15% on incurred costs as an administrative, overhead and
handling  charge.  The initial term of the Agreements, dated September 21, 2000,
is  five  consecutive  years.  All  successive  renewals  will  be  effective
automatically  with  the  lapse  of  the  current  term.

THE  TECHNOLOGIES
-----------------

Duro  Solutions  has continued research and development on the enzyme technology
licensed  from  529473 B.C. Ltd.  All of the activities thus far with respect to
the  licensed  enzyme  technologies  have  occurred  in  a lab on a research and
development  basis.  The  Company  has  also  prepared schematic drawings of its
planned  enzyme and energy production facility.  The Company has not constructed
a  prototype  of  the  gasification  system  it  plans to use to produce energy.

Research  and development is being executed by Dr. Robert Jackman, the Company's
President,  and Timothy Ackah-Sanzah.  Mr. Ackah-Sanzah received his Bachelor of
Science,  with a major in biology and a minor in Chemistry, from Trinity Western
University,  Langley,  British  Columbia.

The Company plans to implement the energy production aspect of its business plan
prior to engaging in any enzyme production.  The Company plans to produce energy
from  steam  turbines powered by the combustion of waste materials, coupled with
the  staged  processing  of  the  gases  released  by  their  combustion
("gasification").  The  enzyme  production  process  that  the  Company has been
researching  creates a combustible pellet by-product, which the Company plans to
combust  in its planned enzyme and energy production facility.  If the demand is
present,  the  Company  may install and operate gasification systems for others.

GASIFICATION
------------

As  a  process  technology  for  the  refining,  chemical  and power industries,
gasification  has  been  in  commercial use for over half a century. In 1999, in
cooperation  with the Gasification Technologies Council and the US Department of
Energy,  SFA  Pacific,  Inc. conducted the World Gasification Survey. A total of
160  commercial  gasification  plants  in  all stages of construction and use in
North  America,  South  America,  Europe,  Asia,  Africa,  and  Australia,  were
surveyed. Total daily capacity of these plants was estimated to be approximately
4,472  billion  BTU,  or the equivalent of approximately 770,000 barrels of oil.


                                        4
<PAGE>
Gasification  processes  of  the past were primarily for the purpose of chemical
production.  However,  gasification  capacity that has been added since 2000 has
been  almost 3:1 in favor of power generation, demonstrating growing electricity
demands  and  deregulation  of the global electricity markets. During the period
between  1990  and  1999, world gasification capacity increased by 50%, with the
addition  of  43 new plants and an approximately 25% increase in the capacity of
the  three  Sasol  plants,  located  in  South Africa, which provide the world's
largest  concentration  of gasification capacity. Between 2000 and 2005, another
41 plants have been projected for start-up, increasing capacity by an additional
58%  and  reflecting  annual  growth  of  almost  10%.

Air  emissions  from gasification plants comply with US Clean Air Act standards.
As air emissions standards become more stringent, gasification technologies will
provide  economic  benefits  due  to  the  lower  cost  of emissions reductions.

The  Company  plans  to  use  existing  gasification  technologies  for  the
cost-effective production of steam and electricity. Gasification is an efficient
and  environmentally  effective  means  of  producing steam and electricity from
solid  or  liquid inputs.  The process involves the iterative capturing of gases
released  by combustion and then combusting those captured gases at successively
higher  temperatures.  The  last  such  combustion  occurs at approximately 3500
degrees  Fahrenheit.  The  Company  plans  to  supply  the  oxygen  needed  for
combustion from the pungent air created by organic processes, such as the enzyme
production  process.

Gasification  minimizes  environmentally  damaging  pollutants  that result from
waste-to-energy incineration, it redirects materials that would traditionally go
to  landfills,  and  it  uses  a  renewable  resource  to  create  clean energy.
Gasification  is  also  a cost effective method of odor control in manufacturing
and  processing facilities.  The Company believes it will provide the additional
benefits  of  reducing  energy costs for the facility and creating cashflow from
the  sale  of  energy  to  industrial  clients  and  the  local  power  grid.

Effective  odor control in processing facilities can be costly, depending on the
size  of  the  facility.  With the use of gasification technologies, process air
from  within  a  facility  can be used in, and enhance the effectiveness of, the
gasification  process. Odor control using gasification can result in significant
cost  savings.  By  gasifying  process  air, odors and emissions that impact the
environment  are  cost  effectively  eliminated.

STABLE  &  NATURAL  ENZYME  PRODUCTION
--------------------------------------

The  global  enzyme  market  is  estimated  to  be about $3 billion. Enzymes are
responsible  for  every  biological  reaction.  They  are  used in processes and
commercial  products  in a wide variety of industries including pharmaceuticals,
biofuels,  bioremediation,  food,  beverages, textiles, leather, pulp and paper,
health,  animal  feeds, and diagnostics to name a few.  Enzyme applications have
been  limited  due  to  the fact that available enzyme products are destroyed or
rendered  inactive  under challenging use conditions, such as high temperatures,
salt  concentrations,  presence  of  solvents,  or  pH  extremes.  The  lack  of
commercially  available  enzymes  with  stable  properties  has  limited  market
expansion  and  growth  of commercial enzyme use.  The Company believes that its
stable  enzymes  -  stable  to  high  temperatures,  solvents,  high  salt
concentrations, and pH extremes - will provide a wider range of applications for
enzyme  use  in  all  industries.

The  Company's  stable  natural  enzymes will be manufactured by fermenting pure
waste  streams such as various sludges, specific organic post-consumer products,
and  industrial  or  commercial  wastes  such  as  bulk dairy or meat processing
wastes. The Company's stable enzyme manufacturing and production operations will
be  setup adjacent to a transfer station, dairy, waste water treatment facility,
pulp  and  paper  plant, or food processor to name only a few opportunities. The
specific  waste  materials  will  be  slurried  and  fermented under controlled,
natural  conditions  to yield stable natural enzymes in concentrated form. These
enzymes are active and stable in high temperatures, in solvents, in pH extremes,
and  in  high salt concentrations. The Company believes they will open up enzyme
applications  in industries that have been held back by other commercial enzymes
that  are  not  stable,  and  are  destroyed or rendered inactive by challenging
conditions of use. If stable enzyme manufacturing is combined with gasification,
the  energy-rich  bulk  solids  byproduct  of  stable enzyme manufacture will be
blended  with other waste materials, pelletized, and used in gasification. Steam
production  resulting from gasification will be used to generate electricity and
for heat in operations. Generated electricity will be used to power the combined
stable  enzyme  and  energy  operation, with any excess sold to other industrial
clients  and/or  the  local  power  grid.


                                        5
<PAGE>
The  selection of specific post-consumer products and sludges as input materials
for  the  stable enzyme manufacturing process enables stable and natural enzymes
to  be  custom  made  to meet the needs of many different enzyme applications. A
variety  of  specific enzymes can be produced from each specific input material.
The  following table includes a few of the potential applications of the enzymes
generated  from  specific  waste  materials.

<TABLE>
<CAPTION>
===================================  ===============================================================================
SPECIFIC WASTE SOURCE                APPLICATIONS OF STABLE ENZYMES PRODUCED FROM SPECIFIC WASTE SOURCE
<S>                                  <C>
-----------------------------------  -------------------------------------------------------------------------------
Wastewater sludges & animal manures  Nutrient enhancers; digestive aids; compost accelerants; deodorizing agents;
                                     leather tanning agents
-----------------------------------  -------------------------------------------------------------------------------
Oil sludges & processing wastes      Oil breakdown; oil recovery; degumming of oils; cleaning agents; detergent
                                     additive; health supplements; digestive aids; pharmaceuticals; bioremediation;
                                     leather tanning agents; pitch control in pulp & paper production
-----------------------------------  -------------------------------------------------------------------------------
Potato wastewater                    Production of sweeteners; ethanol production; digestive aids
-----------------------------------  -------------------------------------------------------------------------------
Cheese whey                          Digestive and health aids; pharmaceuticals; food texture modifying agents
-----------------------------------  -------------------------------------------------------------------------------
Pulp & paper sludge                  Compost accelerants; fiber-size reducing and bleaching agents in pulp & paper
                                     manufacture; ethanol production; de-inking agents
-----------------------------------  -------------------------------------------------------------------------------
Meat trimming & byproducts           Cleaning agents; detergent additives; meat tenderizers; digestive aids; leather
                                     tanning agents
-----------------------------------  -------------------------------------------------------------------------------
Fruit & vegetable wastes             Digestive and health aids; nutrient enhancers; flavor production;
                                     decolorizing/bleaching agents; compost accelerants
-----------------------------------  -------------------------------------------------------------------------------
Offal                                Leather tanning agents; digestive aids; flavor production
===================================  ===============================================================================
</TABLE>


RESEARCH  AND  DEVELOPMENT
--------------------------

No  stable  enzyme  and energy manufacturing and production facilities have been
constructed  as  of  the  date  of  this  annual  report. The Company intends to
purchase an existing waste processing facility permitted to receive 400-tons per
day  of  waste  material,  and  retrofit  the  facility  with  fully  integrated
waste-to-energy  systems,  enzyme  manufacturing  systems,  and  technology
development  capabilities.  The cost of purchasing and retrofitting the facility
is  estimated  at  US$6  million.

MARKETING  AND  SALES
---------------------

Until  the  Company  has an operating facility in place, its marketing and sales
activities  will  be  limited.  The  Company's  stable  enzyme  and gasification
technologies  can  be  applied  (1)  together  in  stand-alone  facilities,  (2)
independent of each other in stand-alone facilities, (3) together in conjunction
with  compatible  operations  such  as  transfer  stations  or  waste generating
facilities,  or (4) independently in conjunction with compatible operations such
as transfer stations or waste generating facilities. The Company plans to own or
enter  into  joint  ventures  with  waste receiving businesses, such as transfer
stations  or  waste  water  treatment  facilities,  or  with  waste  generating
businesses,  such  as  pulp  and paper plants, dairies, wineries, farms, or food
processors.  Gasification  of  dried  and  pelletized  wastes  will  be  used to
generate power for operations, with excess power sold to industrial users and/or
the  local  power  grid.

The Company believes its stable enzymes will command premium prices due to their
stable natural characteristics. Commercial enzymes currently on the market range
in price from $500.00 per ounce to more than $750,000 per ounce.  The Company is
in  the  process  of  determining  which  enzyme  will  be  available  for
commercialization  first.

COMPETITION
-----------

GASIFICATION
------------

As  a  process  technology  for  the  refining,  chemical  and power industries,
gasification  has  been  in  commercial use for over half a century. In 1999, in
cooperation  with the Gasification Technologies Council and the US Department of
Energy,  SFA  Pacific,  Inc. conducted the World Gasification Survey. A total of
160  commercial  gasification  plants  in  all stages of construction and use in
North America, South America, Europe, Asia, Africa, and Australia were surveyed.
Total  daily  capacity  of  these plants was estimated to be approximately 4,472
billion  BTU,  or  the  equivalent  of  over  770,000  barrels  of  oil.


                                        6
<PAGE>
Gasification  processes  of  the past were primarily for the purpose of chemical
production.  However,  gasification  capacity that has been added since 2000 has
been  almost 3:1 in favor of power generation, demonstrating growing electricity
demands  and  deregulation  of the global electricity markets. During the period
between  1990  and  1999, world gasification capacity increased by 50%, with the
addition  of  43 new plants and an approximately 25% increase in the capacity of
the  three  Sasol  plants,  located  in  South Africa, which provide the world's
largest  concentration  of gasification capacity. Between 2000 and 2005, another
41 plants have been projected for start-up, increasing capacity by an additional
58%  and  reflecting  annual  growth  of  almost  10%.  (Source:
http://www.gasification.org  )

Gasification is one of the most efficient and environmentally effective means of
producing  electricity  from  solid  or  liquid  inputs.  (Source:
http://www.gasification.org)  Air  emissions  from  gasification  plants are far
below  US  Clean  Air  Act  standards.  As  air  emissions  standards  increase,
gasification  technologies  will provide economic benefits due to the lower cost
of  emissions  reductions.

The  Company  is  preparing  to  compete  in  this  arena  with  its  three-tier
gasification process.  The Company believes that the technology it has a license
to  use  and  that is being developed with the assistance of 529473 B.C. Ltd. is
currently  unique  to  the  marketplace  and  will  provide  the Company with an
advantage  over  alternative  gasification processes.  At this time, the Company
cannot  predict  whether  its  gasification  technologies  will  be successfully
implemented  or  its  production  of  energy will be competitive with respect to
other  energy  producers  using  their  own  gasification  processes.

ENZYMES
-------

Approximately  70%  of  commercial  enzymes  in  the marketplace are products of
microbial  fermentation.  The  Company  believes that the traditional methods of
batch  fermentation,  relied  upon  by  most  commercial  enzyme  producers, are
inefficient,  expensive, and limiting.  These limitations include the following:

     -    INACTIVE  ENZYMES: The microbial fermentation method, which depends on
          the  use  of  mild  conditions  to  promote  the  growth  of  the
          enzyme-producing  microorganism,  often  produces  an inactive form of
          enzyme.
     -    INEFFECTIVE  WITH NATURAL MATERIALS: The action of the enzyme products
          is  greatest towards synthetic materials but shows poor performance in
          commercial  use  with  natural  materials.
     -    UNNATURAL:  The  genetically  modified  microorganisms used to produce
          over  75%  of today's commercially available enzymes are not naturally
          occurring  and/or  produce  non-natural  products.
     -    RESOURCE  INTENSIVE:  Isolation and purification of the microorganisms
          is  an expensive, time-consuming and resource intensive process, which
          often  involves  trial  and  error  in  the  laboratory.
     -    EXPENSIVE:  Cost of development and manufacture of specific enzymes is
          often  significant,  resulting in high prices for the resulting enzyme
          products  and  processes.
     -    LIMITED: The manufacture of enzymes in batches is inefficient and does
          not  meet  the  individual  needs  of  many  end-users.

Although  a  wide  range  of commercial enzymes are currently on the market, the
Company  believes  there  is  a need for natural enzymes with greater stability.
The  potential  for  substantial  revenues from specialty enzymes has driven the
growth  of  numerous  small-scale  specialty  enzyme  producers,  as well as the
development  and  increased-use  of  high-tech  genetic  engineering  methods to
produce  enzymes  with  desired  properties.  Some  of  these  producers  are
better-funded  than  the  Company  and  may  in  some  circumstances  have  a
time-to-market  advantage  over  the  Company.

The  Company  will  face  substantial competition in markets that do not require
very  stable enzymes. Many of the competing enzyme producers are well-funded and
well staffed. There is no assurance that the Company will be able to effectively
compete  with  these  companies,  which  include:  Novozymes  Inc.,  Genencor
International,  Genentech,  ThermoGen, Inc., AB Enzymes GmbH, Maps, Inc., Enzyme
Solutions  Inc.,  Valley  Research  Inc.,  Textan, and Danlac. At this time, the
Company  has not commenced operations and is unable to determine how competitive
its  products  will  be  in  the  marketplace.


                                        7
<PAGE>
RESEARCH  AND  DEVELOPMENT
--------------------------

The  Company's  future  success in the enzyme market will depend on research and
development  efforts  to enhance its existing enzyme production technologies and
process  and  develop new applications for stable enzymes. For fiscal year ended
September  30, 2001, the Company has contracted out US$1 million on research and
development  of  enzyme  technologies  which will be recognized upon completion.
The  Company anticipates spending between US$2 million and US$5 million over the
next  two  years  on  research  and  development.

INTELLECTUAL  PROPERTY  PROTECTION
----------------------------------

The  License  Agreement  between  the  Company and 529473 B.C. Ltd. provides the
Company  with  the  right  to  use  the stable enzyme-producing technologies and
processes,  and  all  trademarks,  trade  names  and  proprietary  information
associated  with  the  technology  and production processes owned by 529473 B.C.
Ltd.

529473  B.C.  Ltd.,  with  the  assistance  of the Company, is in the process of
filing  for  US  and  Canadian  patent  protection for certain of its processes.
Confidentiality  policies  are  internally implemented by the Company to protect
the  proprietary  information  and  know-how.

EMPLOYEES
---------

As  of  November  30,  2001,  the  Company  had  seven  consultants.  Of  those
consultants,  3  were  classified  as  executive officers, two as administrative
personnel, and two sales and marketing.  The Company's consultants do not belong
to a collective bargaining unit, and the Company is not aware of any labor union
organizing  activity.  The  Company  believes  its future success will depend in
large  part  on  its  continuing  ability  to  attract, train and retain skilled
technical,  sales,  marketing  and  customer  support  personnel.

ITEM  2.  DESCRIPTION  OF  PROPERTY
-----------------------------------

The  Company's  principal executive offices are located at 20436 Fraser Highway,
Langley, British Columbia, V3A 4G2, CANADA.  There it leases approximately 5,000
square feet at a monthly rate of US$3,000 from Brampton Holdings Ltd.  The lease
expires  September  30, 2002 and may be renewed for an additional two year term.

ITEM  3.  LEGAL  PROCEEDINGS
----------------------------

The  Company has been made aware of a lawsuit filed against it, its officers and
directors,  and  others  by  Thermo Tech (TM) Technologies Inc. and subsidiaries
(collectively  "Thermo  Tech").  There are a total of 75 defendants named in the
suit.  The Company has not yet been formally served. Once the Company is served,
it  intends to deny the substance of Thermo Tech's allegations. The Company will
develop  its  formal  technical  legal  response  in  conjunction with its legal
counsel.

Thermo  Tech  alleges  that  the  Company  and  its  officers and directors have
appropriated,  or  in  the  alternative  attempted  to  appropriate,  corporate
opportunities  from  the Plaintiffs through the unauthorized use of confidential
information  and  trade  secrets  owned  by  the  Plaintiffs. As a result of the
alleged  unlawful  actions  of  the  Company  and  its  officers  and directors,
Plaintiffs claim that they have suffered loss, damage and expense. In the prayer
for  relief,  Plaintiffs  seek  the  following  relief  from  the  court:

     -    An  injunction against the Company from unlawfully marketing and using
          the  Thermo  Tech  Process  (defined  in  the  Statement of Claim as a
          process  that  incorporates  the  use  of  thermophilic,  aerobic
          microorganisms  which produce enzymes in a multiple stage fermentation
          process  to  create  high  protein  animal  feed  from organic waste);
     -    Damages  for  unlawfully  marketing and using the Thermo Tech Process;


                                        8
<PAGE>
     -    Damages  for  interference with the Plaintiffs' contractual relations;
     -    Damages  for appropriation of the Plaintiffs' corporate opportunities;
     -    Punitive  damages;
     -    Exemplary  damages;  and
     -    Special  costs,  or  in  the  alternative,  increased  costs.

The  Company believes that Thermo Tech's allegations against it have no basis in
fact,  and  are  without  merit.  As  Thermo Tech states in its press release of
November  20,  2001,  announcing  the  lawsuit:  "[T]he  lawsuit  contains  only
allegations,  not  proven  facts,  and each of these allegations will have to be
proven  by [Thermo Tech] at a trial between the parties." The Company intends to
vigorously  defend this lawsuit and to assert all appropriate counterclaims. Due
to  the  complexities of the lawsuit and the contractual and other relationships
between  the parties to the lawsuit, the Company cannot predict what the outcome
of  the  lawsuit  may  be or reasonably estimate the financial effect associated
with  it.

Except  as  described  above,  to  the  knowledge  of  the  Company's  executive
management  and directors, neither the Company nor its subsidiaries are party to
any other legal proceeding or litigation and none of its property is the subject
of  a  pending legal proceeding and the executive officers and directors know of
no  other  threatened  or  contemplated  legal  proceedings  or  litigation.

ITEM  4.  SUBMISSION  OF  MATTERS  TO  A  VOTE  OF  SECURITY  HOLDERS
---------------------------------------------------------------------

No  matters were submitted to the shareholders during the quarterly period ended
September  30,  2001.


                                        9
<PAGE>
                                     PART II

ITEM  5.  MARKET  FOR  COMMON  EQUITY  AND  RELATED  STOCKHOLDER  MATTERS
-------------------------------------------------------------------------

The  Company's  common  stock  is  traded on the Over-the-Counter Bulletin Board
(OTC-BB)  under  the  symbol  "DEPI."  The  following  table sets forth, for the
periods  indicated,  the  range  of  high  and low sales prices of the Company's
common  stock  as  quoted  by various market makers for the period of October 1,
2000  through  September  30,  2001.

          October 1, 2000 to September 30, 2001:  High*   Low*
                                                  ------  -----
            October to December                   $ 5.03  $1.63
            January to March                      $ 3.31  $1.44
            April to June                         $ 2.40  $2.00
            July to September                     $ 2.30  $2.30

          *The  pricing  information  was  provided  by  Edgar  Filing  System.

On  November 30, 2001, the Company's issued and outstanding common stock totaled
32,876,400  shares, held by approximately 1,000 shareholders of record and by an
undetermined  number  of  additional shareholders through nominee or street name
accounts  with  brokers.

The  Company  has  not  paid  dividends  in  prior years and has no plans to pay
dividends  in the near future.  The Company intends to reinvest its earnings, if
any  are  achieved,  in the continued development and operation of its business.
Any  payment  of  dividends  would  depend upon the Company's pattern of growth,
profitability,  financial  condition,  and  such  other  factors as the Board of
Directors  may  deem  relevant.

RECENT  SALES  OF  UNREGISTERED  SECURITIES

In  October  2000,  the  Company  issued  28,800,000  shares  of common stock in
connection with a voluntary share exchange with the shareholders of Duro Enzymes
Private.  The  issuance  was  exempt  from registration pursuant to Regulation S
under  the  Securities  Act of 1933, as amended, due to the foreign residence of
the  subscribers.  Each  of  the  subscribers  was  provided  with  an  offering
memorandum  prior  to  agreeing  to  the  share  exchange.

ITEM  6.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION OR PLAN OF
--------------------------------------------------------------------------------
OPERATIONS
----------

The  following  discussion  should  be read in conjunction with the consolidated
financial  statements  included  herein. Certain statements contained herein may
constitute  forward-looking  statements, as discussed at the beginning of Part I
of  this annual report. Because such statements include risks and uncertainties,
actual  results  may  differ  materially from those expressed or implied by such
forward-looking  statements.  Factors  that  could  cause  or contribute to such
differences  include  those discussed in the "Outlook: Issues and Uncertainties"
section  of  this  Form  10-KSB.

During  the  year the Company changed the focus of its business from the sale of
gourmet  food  and specialty cheese on the internet to focusing its resources on
constructing  facilities  that  are  designed  to be a source of steam and clean
energy.  The  Company  will  also  license  and manufacture unique, stable, 100%
natural  enzymes.  The  Company  abandoned the equipment and trade name that was
used  to  promote  the  sale  of  the  gourmet  food  and  specialty  cheese.

OVERVIEW

The  Company is a Nevada corporation, incorporated on September 15, 1995.  Since
inception  and  up  through  September 2000, the Company was a development stage
company  focused  on  gourmet  cheese  production  and  distribution.


                                       10
<PAGE>
On  October  16, 2000, the Company acquired Duro Enzymes Products Inc, a private
Nevada  corporation  formed in November 1999, through a voluntary share exchange
with all of the shareholders of Duro Enzymes Private. The former shareholders of
Duro  Enzymes  Private now hold 28,800,000 shares of the Company's common stock.
The  Company  effectively  took  control  of  all  of the assets of Duro Enzymes
Private, including its subsidiaries, as a result of the voluntary share exchange
and  subsequent  merger  of Duro Enzymes Private into the Company. Following the
merger,  the Company changed the focus of its business from the sales of gourmet
and  specialty cheeses over the Internet to its new business of gasification and
stable,  natural  enzyme  production. In connection with the change in business,
new  directors  and  executive  officers were appointed. The Company has carried
forward  an  accumulated  deficit  incurred  during  its  development  stage  of
$1,349,077  from  the  business  of  gourmet  food  and  specialty  cheese.

PLAN  OF  OPERATIONS

Following  the  acquisition  of  Duro  Enzymes  Private on October 16, 2000, the
Business of the Company focused on researching the production of stable enzymes.
The  Company's  business  is  still  in its development stage. Through a license
agreement  executed  between 529473 B.C. Ltd. and Duro Solutions, a wholly-owned
subsidiary  of  the  Company, on September 21, 2000, the Company was granted the
right  to  continue  research and commercial development and use of the licensed
technology  anywhere  in  the  world.  The  Company  spent the fiscal year ended
September  30,  2001,  further developing its business plans and locating a site
for  its  prototype  facility.

Under  the  terms  of the License Agreement, the Company has made a US$2,500,000
promissory  note  bearing interest at a rate of 5% per annum over a period of 10
years  payable  to  529473  B.C.  Ltd.  The  obligation  to make payments on the
promissory  note  does  not  commence  until  the  Company begins selling stable
enzymes.  At  that  time,  the  Company is obligated to pay the entire principal
amount  and  any  accrued interest within five years.  Interest will continue to
accrue  throughout  the  term  of  the note.  In addition, the Company must make
royalty  payments  equal  to 2.5% of gross revenue generated by the Company from
use  of  the  licensed  technologies.  The  royalty payments are to be made on a
quarterly  basis.

Over  the  next  year,  the  Company  plans  to purchase an existing, permitted,
400-ton  per day waste processing facility, and retrofit it to a waste-to-energy
and stable enzyme manufacturing and production facility for an estimated cost of
US$6  million.

The Company has not generated any revenue to date.  If the Company purchases and
retrofits  a  facility  for  its  operations, the facility's ability to generate
operating income will depend upon local tip fee structures and the market demand
for  energy.  The  Company  plans  to  begin producing enzymes only after it has
succeeded  in  putting  in  place  an  energy-producing  gasification  system.

Operation  costs  will  depend  on  a  number of factors, including local wages,
utilities pricing, taxes, finance fees, logistics of obtaining raw materials and
end  product  distribution.  The  Company's most significant expense to date has
been  the  acquisition  of  the  license  rights to the stable enzyme production
technologies.

The  Company  changed  its  fiscal  year end from December 31 to September 30 by
unanimous  consent  of  the  Board  of  Directors  on  December  15,  2000.

LIQUIDITY  AND  CAPITAL  RESOURCES

No material commitments for capital expenditures were made during the year ended
September 30, 2001.  During the nine months ended September 30, 2000 Duro Enzyme
Private  arranged  for  a  US$2.5  Million long-term Note Payable to acquire the
License  of  the  enzyme  technology.

The  Company  estimates  the  cost  of  building  a manufacturing and processing
facility  at  US$6 Million, with under US$1 Million needed for initial operation
of  the  facility  during  the first year.  Repayment of the US$2.5 Million note
will  begin  six  months after commercial revenue is earned by the Company, with
full  repayment  of  the  note  required  over  the  following  five  years.

As  of  September  30,  2001,  the  Company  had  a net stockholders' deficit of
$635,697,  with  accumulated  losses  during the development stage of $2,006,765
including  a  loss  of  $657,688  during  the current year.  The current working
capital  deficit  is $257,957 compared with a working capital deficit of $25,938
the  previous  year.  There can be no assurance that the Company will be able to
continue  as  a  going  concern  or  achieve  material  revenues  or  profitable
operations.


                                       11
<PAGE>
The  Company  plans  to utilize a combination of internally generated funds from
operations  over  the next year, potential debt and/or equity financings to fund
its short-term and long-term growth.  The availability of future financings will
depend  on  market  conditions.  A  portion of the funds may be used to grow the
business  through  acquisitions  of  other  businesses.

The  forecast  of  the  period  of  time  through  which the Company's financial
resources  will be adequate to support operations is a forward-looking statement
that  involves  risks  and  uncertainties.  The  actual funding requirements may
differ  materially  from this as a result of a number of factors including plans
to  rapidly  expand its new operations. There can be no guarantee that financing
adequate  to  carry  out  the Company's business plan will be available on terms
acceptable  to  the  Company,  or  at  all.

EFFECT  OF  FLUCTUATIONS  IN  FOREIGN  EXCHANGE  RATES

The Company's reporting and functional currency is the US dollar. Currently, all
of  the  Company's  operations  are  located in Canada. Transactions in Canadian
dollars  have  been  translated into U.S. dollars using the current rate method,
such  that  assets  and  liabilities  are translated at the rates of exchange in
effect  at the balance sheet date and revenue and expenses are translated at the
average rates of exchange during the appropriate fiscal period. As a result, the
carrying  value of the Company's investments in Canada is subject to the risk of
foreign  currency  fluctuations.  Additionally,  any  revenues received from the
Company's international operations in other than U.S. dollars will be subject to
foreign  exchange  risk.

RECENT  ACCOUNTING  PRONOUNCEMENTS

In  June  1998,  the  Financial  Accounting  Standards Board issued Statement of
Financial  Accounting  Standards No. 133, "Accounting for Derivative Instruments
and  Hedging  Activities"  (SFAS  No.  133).  SFAS No. 133 requires companies to
recognize  all  derivatives  contracts  as  either  assets or liabilities in the
balance sheet and to measure them at fair value.  If certain conditions are met,
a  derivative  may be specifically designated as a hedge, the objective of which
is  to  match  the  timing of gain or loss recognition on the hedging derivative
with the recognition of (i) the changes in the fair value of the hedged asset or
liability  that  are attributable to the hedged risk or (ii) the earnings effect
of  the  hedged  forecasted  transaction.  For  a derivative not designated as a
hedging  instrument,  the  gain or loss is recognized in income in the period of
change.  SFAS  No.  133  is  effective  for  all fiscal quarters of fiscal years
beginning  after  June  15,  2000.

Historically,  the  Company has not entered into derivatives contracts either to
hedge existing risks or for speculative purposes.  Accordingly, the Company does
not  expect  adoption  of  the  new  standard  on  January 1, 2001 to affect its
financial  statements.

In  December  1999,  the  SEC  staff released Staff Accounting Bulletin No. 101,
"Revenue  Recognition  in  Financial  Statements" ("SAB 101").  SAB 101 provides
interpretive guidance on the recognition, presentation and disclosure of revenue
in  the  financial  statements.  SAB  101  must  be  applied  to  the  financial
statements  no  later  than  the quarter ending September 30, 2000.  The Company
does not believe that the adoption of SAB 101 will have a material affect on the
Company's  financial  results.

In  March  2000,  the Financial Accounting Standards Board issued Interpretation
No.  44  ("FIN  44")  Accounting  for  Certain  Transactions  Involving  Stock
Compensation,  an  Interpretation  of  APB Opinion No. 25.  FIN 44 clarifies the
application  of  APB  No.  25 for (a) the definition of employee for purposes of
applying  APB  No. 25, (b) the criteria for determining whether a plan qualifies
as  a  non-compensatory  plan,  (c)  the  accounting  consequences  of  various
modifications  to the terms of a previously fixed stock option or award, and (d)
the  accounting  for  an  exchange  of  stock  compensation awards in a business
combination.  FIN  44  is  effective July 2, 2000, but certain conclusions cover
specific  events that occur after either December 15, 1998, or January 12, 2000.
The  Company  will  adopt  FIN  44  in accounting for the stock options granted.


                                       12
<PAGE>
In  March  2000,  EITF  00-2  "Accounting  for  Web  Site Development Costs" was
released.  EITF 00-2 provides guidance on how an entity should account for costs
involved in such areas as planning, developing software to operate the web site,
graphics,  content, and operating expenses.  EITF 00-2 is effective for web site
development  costs  incurred  for fiscal quarters beginning after June 30, 2000.

OUTLOOK:  ISSUES  AND  UNCERTAINTIES

Shareholders  and  prospective  purchasers  of the Company's Common Stock should
carefully  consider  the  following  risk  factors  in  addition  to  the  other
information  appearing  in  this  Annual  Report  on  Form  10-KSB.

BUSINESS  RISKS
---------------

     THE  IMPLEMENTATION  OF  THE  COMPANY'S  BUSINESS  PLAN  DEPENDS  UPON  ITS
     CONTINUED  RELATIONSHIP  WITH  529473  B.C.  LTD.

The  Company's business depends upon technologies and know-how that are owned by
529473  B.C.  Ltd.  and upon the provision of technical expertise by 529473 B.C.
Ltd.  to  the  Company. The Company has entered into Agreements with 529473 B.C.
Ltd.  both  for  use of its technologies to make some of the commercial products
that it intends to produce and sell and for consulting services used to continue
the  research  and  development  of  the  proprietary  gasification  and  stable
enzyme-producing  technologies.  If  the  Company has a disagreement with 529473
B.C.  Ltd.  that  results  in  the severing of its relationship with 529473 B.C.
Ltd.,  the  Company  will  be  unable to implement its business plan or continue
operations  as  planned,  which  would  have  a  severe impact on its ability to
generate  revenue  in  the  future.

     THE  COMPANY  MAY  REQUIRE  ADDITIONAL  EQUITY  FINANCING, WHICH MAY NOT BE
     AVAILABLE  AND  MAY  DILUTE  THE  OWNERSHIP  INTERESTS  OF  INVESTORS.

The  Company's  ultimate  success will depend on its ability to raise additional
capital.  No  commitments  to  provide  additional  funds  have  been  made  by
management  or  other  shareholders.  The  Company  has  not  investigated  the
availability,  source  or  terms that might govern the acquisition of additional
financing.  When  additional capital is needed, there is no assurance that funds
will be available from any source or, if available, that they can be obtained on
terms acceptable to the Company.  If unavailable, the Company's operations could
be  severely limited, and it may not be able to implement its business plan.  If
equity  financing  is  used  to  raise additional working capital, the ownership
interests  of  existing  shareholders  may  be  diluted.

     THE COMPANY'S OPERATING RESULTS ARE LIKELY TO FLUCTUATE SIGNIFICANTLY WHICH
     COULD  INCREASE  THE  VOLATILITY  OF  ITS  STOCK  PRICE.

As  a  result  of  the Company's limited operating history and the planned rapid
expansion  of  its  business  operations,  the  Company's  quarterly  and annual
revenues  and  operating  results are likely to fluctuate from period to period.
For  this  reason,  you  should  not rely on period-to-period comparisons of the
Company's  financial  results  as  indications of future results.  The Company's
future  operating  results  could  fall  below the expectations of public market
analysts  or  investors  and significantly reduce the market price of its common
stock.  Fluctuations  in  the  Company's  operating  results  could increase the
volatility  of  its  stock  price.

     THE  COMPANY'S  DEPENDENCE ON RELATIONSHIPS WITH BUSINESSES AND GOVERNMENTS
     OUTSIDE  OF  THE UNITED STATES MAY NEGATIVELY AFFECT ITS ABILITY TO OPERATE
     ITS  BUSINESS  AS  PLANNED.

The  Company  depends  on  its  ability  to  establish  and  maintain successful
relationships  with  businesses  and  governments  located outside of the United
States.  If  the Company is unable to establish and maintain such relationships,
it will not be able to implement the business plan in its current configuration,
which  will  affect  both its revenue stream and profit potential.  In addition,
the  Company  faces  political  sovereign  risks  of  conducting  international
business,  including  risks  of  changing  economic conditions, which may have a
material  adverse  effect  on  its  ability  to  expand its operations globally.


                                       13
<PAGE>
     THE  COMPANY  MAY  BE  UNABLE  TO  PROTECT ITS INTELLECTUAL PROPERTY, TRADE
     SECRETS  AND  KNOW-HOW  WHICH WOULD REMOVE A BARRIER TO COMPETITION AND MAY
     DIRECTLY  AFFECT  THE  AMOUNT  OF  REVENUE  IT  GENERATES.

The  Company depends heavily on licensed technology to produce unique stable and
natural  enzymes.  The Company is dependent on its ability to keep trade secrets
and  obtain patents on its technologies as well as on its ability to develop new
processes,  technologies  and  products  to  meet  the needs of its marketplace.
Although  the  Company  intends to employ various methods, including trademarks,
patents,  copyrights  and confidentiality agreements with employees, consultants
and  third  party  businesses,  to  protect  its intellectual property and trade
secrets,  there  can  be  no  assurance  that  it  will  be able to maintain the
confidentiality  of  any  of  its  proprietary  technologies,  know-how or trade
secrets,  or that others will not independently develop substantially equivalent
technology.  The  failure  or  inability  to  protect  these rights could have a
material  adverse  effect  on  the  Company's  operations.

     THE  COMPANY  DEPENDS  UPON  A SMALL NUMBER OF KEY PERSONS TO IMPLEMENT ITS
     BUSINESS  PLAN,  AND  THE  LOSS  OF  ANY  OF  THEM  MAY AFFECT ITS BUSINESS
     OPERATIONS.

The  Company  is dependent on several key employees and consultants to implement
its  business plan, and the loss of any of them may affect the Company's ability
to  provide  the  required quality of service and technical support necessary to
achieve  and  maintain a competitive market position. There is no assurance that
these  key  employees  and  consultants  will  continue  to manage the Company's
affairs  in  the  future.  The  Company  has not obtained key man insurance with
respect  to  any  of  its  employees.

     THE  COMPANY  MAY  NOT BE ABLE TO EFFECTIVELY MANAGE ITS GROWTH WHICH COULD
     HAVE  A  MATERIAL  EFFECT  ON  ITS  BUSINESS  OPERATIONS.

The  Company's  ability to manage its growth depends in part upon its ability to
develop and expand operating, management, information and financial systems, and
production  capacity,  which  may  significantly  increase  its future operating
expenses.  No  assurance can be given that it will grow in the future or that it
will  be  able  to  effectively manage such growth.  Its inability to manage its
growth  successfully  could  have  a  material  adverse  effect on its business,
financial  condition and results of operations.  The Company cannot successfully
implement its business model if it fails to manage its growth. The Company plans
to  rapidly  and  significantly  expanded  its  operations  domestically  and
internationally  and  anticipates  further expansion to take advantage of market
opportunities.

INVESTMENT  RISK
----------------

     CONCENTRATION OF OWNERSHIP OF DIRECTORS, OFFICERS AND SIGNIFICANT EMPLOYEES
     MAY  REDUCE  THE  CONTROL  BY  OTHER  SHAREHOLDERS  OVER  THE  COMPANY.

The Company's directors, officers and other control persons own or exercise full
or  partial  control  over  more  than 14.3% of the Company's outstanding common
stock.  As  a result, other investors in the Company's common stock may not have
much  influence  on corporate decision-making. In addition, the concentration of
control  over  the  Company's  common  stock  among the insiders could prevent a
change  in  control  of  the  Company.

     THE  COMPANY'S  COMMON  STOCK IS CONSIDERED A "PENNY STOCK", WHICH MAKES IT
     MORE  DIFFICULT  TO  SELL  THAN  AN  EXCHANGE-TRADED  STOCK.

The  Company's  securities are subject to the Securities and Exchange Commission
rule  that  imposes special sales practice requirements upon broker-dealers that
sell  such  securities  to  other  than  established  customers  or  accredited
investors.  For purposes of the rule, the phrase "accredited investor" means, in
general  terms,  institutions  with  assets  exceeding $5,000,000 or individuals
having net worth in excess of $1,000,000 or having an annual income that exceeds
$200,000  (or  that,  combined  with  a  spouse's income, exceeds $300,000). For
transactions  covered  by  the  rule,  the  broker-dealer  must  make  a special
suitability  determination for the purchaser and receive the purchaser's written
agreement  to  the  transaction  prior  to  the sale. Consequently, the rule may
affect  the  ability of purchasers of the Company's securities to buy or sell in
any  market  that  may  develop.


                                       14
<PAGE>
In  addition,  the  Securities  and  Exchange Commission has adopted a number of
rules  to  regulate "penny stocks." (A "penny stock" is any equity security that
has  a  market  price  of less than $5.00 per share or with an exercise price of
less  than  $5.00  per share, subject to certain exceptions). Such rules include
Rules  3a51-1,  15g-1,  15g-2,  15g-3,  15g-4, 15g-5, 15g-6, and 15g-7 under the
Securities  and  Exchange  Act of 1934, as amended. The rules may further affect
the  ability  of  owners of the Company's shares to sell their securities in any
market  that  may develop for them. Shareholders should be aware that, according
to  the  Securities and Exchange Commission Release No. 34-29093, the market for
penny stocks has suffered in recent years from patterns of fraud and abuse. Such
patterns  include:

     -    control  of the market for the security by one or a few broker-dealers
          that  are  often  related  to  the  promoter  or  issuer;
     -    manipulation  of  prices through prearranged matching of purchases and
          sales  and  false  and  misleading  press  releases;
     -    "boiler  room"  practices  involving  high  pressure sales tactics and
          unrealistic  price  projections  by  inexperienced  sales  persons;
     -    excessive and undisclosed bid-ask differentials and markups by selling
          broker-dealers;  and
     -    the  wholesale  dumping  of  the  same  securities  by  promoters  and
          broker-dealers  after prices have been manipulated to a desired level,
          along  with  the  inevitable  collapse of those prices with consequent
          investor  losses.

     THE  ISSUANCE  OF  ADDITIONAL  SHARES  MAY  HAVE THE EFFECT OF DILUTING THE
     INTEREST  OF  SHAREHOLDERS.

Any  additional issuances of common stock by the Company from its authorized but
unissued  shares  may  have  the  effect  of diluting the percentage interest of
existing  shareholders.  Out  of  the  Company's  160,000,000  authorized common
shares, 127,123,600 or approximately 79.5% remain unissued at November 30, 2001.
The  Board  of  Directors has the power to issue such shares without shareholder
approval.  None of the 40,000,000 authorized preferred shares of the Company are
issued. The Company fully intends to issue additional common shares or preferred
shares  in  order  to  raise  capital to fund its business operations and growth
objectives  or  as  compensation for services rendered on behalf of the Company.

     BOARD  OF  DIRECTORS'  AUTHORITY TO SET RIGHTS AND PREFERENCES OF PREFERRED
     STOCK  MAY  PREVENT  A  CHANGE  IN CONTROL BY STOCKHOLDERS OF COMMON STOCK.

Preferred  shares  may  be  issued  in  series  from  time  to  time  with  such
designation,  rights,  preferences  and  limitations  as  the Company's Board of
Directors  determines by resolution and without shareholder approval. This is an
anti-takeover  measure. The Board of Directors has exclusive discretion to issue
preferred  stock  with rights that may trump those of common stock. The Board of
Directors  could  use  an  issuance  of  Preferred Stock with dilutive or voting
preferences  to  delay,  defer  or prevent common stockholders from initiating a
change  in control of the Company or reduce the rights of common stockholders to
the  net  assets upon dissolution. Preferred stock issuances may also discourage
takeover  attempts  that  may  offer premiums to holders of the Company's common
stock.

     STOCKHOLDERS  DO  NOT  HAVE THE AUTHORITY TO CALL A SPECIAL MEETING THEREBY
     DISCOURAGING  TAKEOVER  ATTEMPS.

Pursuant to the Company's articles of incorporation, only the Company's Board of
Directors  has  the power to call a special meeting of the stockholders, thereby
limiting  the  ability  of  stockholders  to  effect  a change in control of the
Company.

     THE  COMPANY  DOES NOT ANTICIPATTE PAYING DIVIDENDS TO ITS SECURITY HOLDERS
     IN  THE  FORESEEABLE FUTURE WHICH MAKES INVESTMENT IN ITS STOCK SPECULATIVE
     OR  RISKY.


                                       15
<PAGE>
The  Company  has not paid dividends on its common stock and does not anticipate
paying  dividends  on  its  common stock in the foreseeable future. The Board of
Directors  has  sole  authority  to  declare  dividends payable to the Company's
shareholders.  The  fact  that  the  Company  has  not  and does not plan to pay
dividends  indicates  that  the  Company  must use all of its funds generated by
operations for reinvestment in its operating activities and also emphasizes that
the Company may not continue as a going concern. Investors also must evaluate an
investment  in  the  Company  solely  on the basis of anticipated capital gains.

     LIMITED  LIABILITY  OF  THE  COMPANY'S EXECUTIVE OFFICERS AND DIRECTORS MAY
     DISCOURAGE  STOCKHOLDERS  FROM  BRINGING  A  LAWSUIT  AGAINST  THEM.

The Company's articles of incorporation and bylaws contain provisions that limit
the  liability of directors for monetary damages and provide for indemnification
of  officers  and  directors.  These provisions may discourage stockholders from
bringing a lawsuit against officers and directors for breaches of fiduciary duty
and may also reduce the likelihood of derivative litigation against officers and
directors even though such action, if successful, might otherwise have benefited
the  stockholders. In addition, a stockholder's investment in the Company may be
adversely  affected  to  the  extent  that costs of settlement and damage awards
against  officers  or  directors  are  paid  by  the  Company  pursuant  to  the
indemnification  provisions  of  the  articles of incorporation and by-laws. The
impact on a stockholder's investment in terms of the cost of defending a lawsuit
may  deter  the  stockholder  from  bringing  suit  against one of the Company's
officers  or  directors.  The  Company  has  been advised that the SEC takes the
position that this provision does not affect the liability of any director under
applicable  federal  and  state  securities  laws.


ITEM  7.  FINANCIAL  STATEMENTS
-------------------------------

Financial  statements  and  supplementary  data  are set forth on pages F-1 thru
F-11.

ITEM  8.  CHANGES  IN  AND  DISAGREEMENTS  WITH  ACCOUNTANTS  ON  ACCOUNTING AND
--------------------------------------------------------------------------------
FINANCIAL  DISCLOSURE
---------------------

From  Inception, December 1998, through January 8, 2001, the Company's principal
accountant  was  Hawkins Accounting of Morgan Hill, California.  From inception,
November 1999, through October 2000, Duro Enzymes Private's principal accountant
was  Raber  Mattuck  of Vancouver, British Columbia, Canada. On January 8, 2001,
management of the Company dismissed Hawkins with the expectation of engaging BDO
Dunwoody,  LLP,  of  Vancouver,  British  Columbia,  as  its  independent public
accountants  to  audit  its financial statements.  The change of accountants was
reported  on  a Form 8-K dated January 8, 2001 and filed with the SEC on January
12,  2001,  and  was  ratified  by  the  Company's  stockholders  at  a  special
stockholders'  meeting  held  on  February  5,  2001.

The Company was subsequently unable arrive at acceptable terms for engagement of
BDO  Dunwoody.  BDO  Dunwoody,  therefore,  did  not  perform  any serves as the
Company's  principal  accountant  at  any  time  during  the  fiscal  year ended
September  30,  2001.  The Company then engaged Raber Mattuck for the purpose of
reviewing  its  interim financial statements for the quarters ended December 31,
2000,  March 31, 2001, and June 30, 2001.  In order to maintain consistency with
respect  to  its  audited  financial statements, however, the Company later once
again  engaged  Hawkins  Accounting as its principal accountant for the audit of
its  financial statements for the year ended September 30, 2001.  On October 19,
2001,  the  Board  of  Directors  of the Company rescinded its engagement of BDO
Dunwoody  and  approved  the  engagement  of Hawkins Accounting as its principal
accountant.

The Company believes, and has been advised by Raber Mattuck that it concurs with
such  belief, that, for the interim period from October 1, 2000 through June 30,
2001,  the Company and Raber Mattuck did not have any disagreement on any matter
of  accounting  principles  or  practices,  or  financial  statement disclosure.

The  Company  has  requested  that BDO Dunwoody and Raber Mattuck each furnish a
letter  addressed to the Securities and Exchange Commission stating whether they
agree  with  the  above  statements.  Those  letters are attached to this annual
report  as  Exhibits  16.1  and  16.2  respectively.


                                       16
<PAGE>
                                    PART III

ITEM  9.  DIRECTORS,  EXECUTIVE  OFFICERS,  PROMOTERS  AND  CONTROL  PERSONS;
-----------------------------------------------------------------------------
COMPLIANCE  WITH  SECTION  16(A)  OF  THE  EXCHANGE  ACT
--------------------------------------------------------

The following individuals were appointed directors and executive officers of the
Company  on  September  29,  2000:

        Robert  L.  Jackman   Director,  President  and  Treasurer
        Dean  Branconnier     Director  and  Vice  President
        Jolene  Fuller        Director and Secretary (Resigned December 21,2000)

On  December  21,  2000  the  Board  of  Directors  of  the Company accepted the
resignation  of  Jolene  Fuller  and  appointed:

        Chad  Burback         Director  and  Secretary

The  following  table sets forth the name, age and position of each Director and
Executive  Officer  of  the  Company  as  of  September  30,  2001.

     NAME               AGE                      POSITION
     -----------------  ---  ------------------------------------------------
     Robert L. Jackman   39  President, Treasurer and Director of Duro Enzyme

     Dean Branconnier    33  Vice President and Director of Duro Enzyme

     Chad Burback        26  Secretary and Director of Duro Enzyme


DR.  ROBERT  L.  JACKMAN  -  PRESIDENT,  TREASURER  AND  DIRECTOR
-----------------------------------------------------------------

Prior  to  becoming  a  member of the Board and President of Home.Web, Inc., Dr.
Robert  Jackman  assisted  with starting and organizing the Company.  Currently,
Dr.  Jackman  is  a research and development and management consultant to 529473
B.C.  Ltd.  (since  1998)  and  Earthscape  Maintenance Inc. (since 1997).  As a
consultant,  he  has  assisted  in  the management of corporate research and new
product  and technology development, coordinated experimental research projects,
provided  technical  support  services,  assisted  with day-to-day management of
operations,  assisted  with  promotion  of  the  companies  and  their products,
assisted  with  preparation of patent applications, and provided quality control
of  facilities.  In 1994 and 1995, Dr. Jackman worked as a research associate at
the  University  of Guelph in Guelph, Ontario, Canada.  As a research associate,
he  conducted  research  studies  on  food  texture-structure  relationships and
published  his  findings.  Dr.  Jackman is an author of six book chapters and 20
scientific  research  papers.  He received a Ph.D. in Food Science in 1992 and a
Masters  of Science degree in 1988 from the University of Guelph.  He also has a
Bachelor  of  Science  degree  from the University of British Columbia, which he
received  in  1985.

MR.  DEAN  BRANCONNIER  -  VICE  PRESIDENT  AND  DIRECTOR
---------------------------------------------------------

Over  the past year, Mr. Dean Branconnier has assisted with the organization and
development  of  the Company.  Prior to the year 2000, Mr. Branconnier was Plant
Manager  for  Richmond Bio Conversion Inc. in Richmond, British Columbia, Canada
(1998-2000)  and  for  Hamilton Bio Conversion Inc. in Hamilton, Ontario, Canada
(1995-1998).  As  Plant  Manager,  Mr.  Branconnier had the following duties and
responsibilities:  assist  with  project  schedules  and construction contracts;
plant  operations  and  start  up;  maintain a daily log of all plant events and
manage daily operations; oversee all office administration; manage expenditures;
ensure compliance with permits; conduct performance reviews of employees; ensure
plant  safety  and  security;  and  staff  the  plants.

MR.  CHAD  BURBACK  -  SECRETARY  AND  DIRECTOR
-----------------------------------------------


                                       17
<PAGE>
Over  the  past  year,  Mr.  Chad Burback has assisted with the organization and
development  of  the  Company.  Mr.  Burback  was Plant Manager for Hamilton Bio
Conversion Inc. in Hamilton, Ontario, Canada (1998-2001).  From 1995 to 1998 Mr.
Burback  was  the  Plant Manager for Brampton Bio Conversion Inc., a Depackaging
and  Recycling facility in Brampton, Ontario, Canada.  As Plant Manager for each
facility,  Mr.  Burback  was responsible for the expansion of the facilities and
had  the  following  duties and responsibilities:  assist with project schedules
and  construction contracts; operations control and management; maintain a daily
log of all plant events; oversee all office administration; manage expenditures;
ensure compliance with permits; conduct performance reviews of employees; ensure
plant  safety  and  security;  and  staff  the  plants.


SECTION  16(A)  BENEFICIAL  OWNERSHIP  REPORTING  COMPLIANCE

Directors,  officers  and  beneficial owners of more than 10% of the outstanding
common  stock  of  the  Company  are required by Section 16(a) of the Securities
Exchange  Act  of 1934 to report to the Securities and Exchange Commission their
transactions  in,  and  beneficial  ownership  of,  the  Company's common stock,
including  any  grants  of  options  to purchase common stock.  Dr. Jackman, Mr.
Branconnier,  Ms.  Fuller and Mr. Burback have filed with the SEC Forms 3 and 4.
These  forms  were  filed  after  their  due  dates  as  follows:

<TABLE>
<CAPTION>
                                                      NUMBER OF TRANSACTIONS NOT
NAME OF REPORTING PERSON    NUMBER OF LATE REPORTS    REPORTED ON A TIMELY BASIS
<S>                       <C>                         <C>

Robert Jackman                         2                           1
------------------------  --------------------------  --------------------------
Dean Branconnier                       2                           1
------------------------  --------------------------  --------------------------
Jolene Fuller                          2                           1
------------------------  --------------------------  --------------------------
Chad Burback                           1                           0
------------------------  --------------------------  --------------------------
</TABLE>


The  Company  has  received  a  written  representation  from  Dr.  Jackman, Mr.
Branconnier,  Mr.  Burback  and  Ms.  Fuller  that  no  Forms  5  are  required.

ITEM  10.  EXECUTIVE  COMPENSATION
----------------------------------

The following table sets forth the compensation that the Company has paid to its
President  for the year ended September 30, 2001.  No executive officer received
more  than US$100,000 in annual compensation during the year ended September 30,
2001.  The  Company  does  not  currently have a long-term compensation plan and
does  not  grant any long-term compensation to its executive officers. The table
does not reflect certain personal benefits, which in the aggregate are less than
ten  percent  of  the  President's  salary and bonus.  No other compensation was
granted  for  the  periods  covered.


<TABLE>
<CAPTION>
                                              SUMMARY COMPENSATION TABLE



                                                                            Long Term Compensation
                                                                    ------------------------------------
                                        Annual Compensation                  Awards            Payouts
                               -----------------------------------  ------------------------  ----------
Name                                                      Other     Restricted   Securities
and                                                       Annual       Stock     Underlying      LTIP      All Other
Principal                       Consulting               Compensa    Award(s)     Options/     Payouts     Compensat
Position                 Year    fees ($)    Bonus ($)   tion ($)       ($)       SARs (#)       ($)        ion ($)
-----------------------  ----  ------------  ---------  ----------  -----------  -----------  ----------  -----------
<S>                      <C>   <C>           <C>        <C>         <C>          <C>          <C>         <C>

Robert Jackman           2001  $ 18,000 (1)  N/A        $        0  N/A                    0  N/A         $         0
(President & Treasurer)
-----------------------  ----  ------------  ---------  ----------  -----------  -----------  ----------  -----------
<FN>

(1)  All  amounts  were  accrued to FL Tech Inc., an Ontario corporation, of which Dr. Jackman is sole principal, for
services  rendered  by  Dr.  Jackman  to  the  Company.
</TABLE>


                                       18
<PAGE>
During  the  year  ended  September  30,  2001,  the  Company hired consultants,
attorneys  and  independent  accountants  to assist management.  The consultants
received  $88,000  in  fees,  the  attorneys  received  $55,888  in  fees,  the
independent  accountants  received  $9,518  in  fees and the executives received
$42,000  in  fees.

COMPENSATION  OF  DIRECTORS

Directors  are not compensated for their service as directors. All directors are
reimbursed  for  any  reasonable  expenses  incurred in the course of fulfilling
their  duties  as  a  director  of  the  Company.

EMPLOYMENT  CONTRACTS

The  Company  does not have employment contracts with its executive officers and
directors.  The  Company may in the future execute written consulting agreements
with  the  consulting companies owned by its executive officers and consultants.

ITEM  11.  SECURITY  OWNERSHIP  OF  CERTAIN  BENEFICIAL  OWNERS  AND  MANAGEMENT
--------------------------------------------------------------------------------

The following table sets forth as of December 14, 2001 certain information known
to the Company regarding the beneficial ownership of the Company's common stock,
and as adjusted to reflect the share ownership for (i) each executive officer or
director  of  the  Company  who  beneficially owns shares; (ii) each shareholder
known to the Company to beneficially own five percent or more of the outstanding
shares  of its common stock; and (iii) all executive officers and directors as a
group.  The  Company  believes  that  the  beneficial owners of the common stock
listed  below,  based  on  information  furnished  by  such  owners,  have  sole
investment  and  voting  power with respect to such shares, subject to community
property  laws  where  applicable.  The  individuals  listed  in  the  table are
accessible  at  the  following  address:  20436 Fraser Highway, Langley, British
Columbia,  CANADA,  V3A  4G2.

<TABLE>
<CAPTION>
                                                                                PERCENTAGE OF
NAME AND POSITION                                          NUMBER OF SHARES  OUTSTANDING SHARES
---------------------------------------------------------  ----------------  -------------------
<S>                                                        <C>               <C>
Robert L. Jackman - President, Treasurer and Director             1,500,000                 4.6%
---------------------------------------------------------  ----------------  -------------------
Dean Branconnier - Vice President and Director                    1,600,000                 4.9%
---------------------------------------------------------  ----------------  -------------------
Chad Burback - Secretary and Director                             1,600,000                 4.9%
---------------------------------------------------------  ----------------  -------------------
Jolene and Fred Fuller - Shareholders (husband & wife)            3,125,000                9.51%
---------------------------------------------------------  ----------------  -------------------
Terri and Lyle Veillet - Shareholders (husband & wife)            3,125,000                9.51%
---------------------------------------------------------  ----------------  -------------------
Shane & Josie Branconnier - Shareholders (husband & wife)         3,125,000                9.51%
---------------------------------------------------------  ----------------  -------------------

ALL CURRENT DIRECTORS AND
OFFICERS AS A GROUP (3 Persons)                                   4,700,000                14.3%
---------------------------------------------------------  ----------------  -------------------
</TABLE>


CHANGE  IN  CONTROL

The  Company  is  not  aware  of  any  arrangement  that would upset the control
mechanisms  currently  in  place.  Although it is conceivable that a third party
could  attempt  a  hostile takeover of the Company, the Company has not received
notice  of  any  such  effort.

ITEM  12.  CERTAIN  RELATIONSHIPS  AND  RELATED  TRANSACTIONS
-------------------------------------------------------------

On  September  14,  2000,  the  inventors  and  former  owners  of  the  stable
enzyme-production  technology  licensed  to  Duro Solutions by 529473 B.C. Ltd.,
transferred  ownership of their intellectual property rights to 529473 B.C. Ltd.
for  a  nominal  amount.  529473  B.C.  Ltd.  is  owned by Mr. Ren  Branconnier;
accordingly  he  is  the ultimate beneficiary of all agreements and arrangements
between  the  Company  and  529473  B.C.  Ltd.


                                       19
<PAGE>
On  September  21,  2000,  the  Company,  through its subsidiaries, acquired the
license  to  use  the  intellectual  property.  Under  the  terms of the License
Agreement,  the Company has made a US$2,500,000 promissory note bearing interest
at  a rate of 5% per annum over a period of 10 years payable to 529473 B.C. Ltd.
The  obligation  to make payments on the promissory note does not commence until
the  Company  begins  selling  stable  enzymes.  At  that  time,  the Company is
obligated  to  pay  the  entire principal amount and any accrued interest within
five  years.  Interest  will continue to accrue throughout the term of the note.
In  addition,  the  Company  must  make  royalty payments equal to 2.5% of gross
revenue  generated  by  the  Company  from use of the licensed technologies. The
royalty  payments  are to be made on a quarterly basis. Any further developments
of  the  technologies  by  the  Company  are to be owned by 529473 B.C. Ltd. and
licensed  to  Duro  Solutions.  Duro Solutions must assist 529473 B.C. Ltd. with
protection  of  its  intellectual  property  through  patent  applications  and
trademark  registrations.

Also on September 21, 2000, the Company became party to Research and Development
Services Agreements with 529473 B.C. Ltd. Under the terms of the Agreements, the
Company  and  its subsidiaries have agreed to retain the services of 529473 B.C.
Ltd. to provide research, development, design, and related consultations. 529473
B.C.  Ltd.  will receive a consulting fee at a standard rate, established by the
consultants,  and  will  charge  an  additional  15%  on  incurred  costs  as an
administrative,  overhead  and  handling  charge.  The  initial  term  of  the
Agreements,  dated September 21, 2000, is five consecutive years. All successive
renewals  will  be  effective  automatically with the lapse of the current term.

As  a  result  of the Company acquiring the License and accrued interest, 529473
B.C. Ltd. is owed $2,627,740 under a note payable with annual interest of 5% per
annum.

During  the  fiscal  year  ended  September  30,  2001, the Company entered into
short-term  loans  with  529473  B.C.  Ltd.,  totaling  $107,833  at  year  end.

During  the  fiscal  year  ended  September  30,  2001, the Company entered into
transactions  for  consulting  services  with  7  companies  that  are  owned or
controlled  by shareholders or creditors of the Company.  At September 30, 2001,
the  amount  outstanding  and  unpaid  is  $120,000.

The Company also leases office space from Brampton Holdings Ltd., which is owned
by  Sharon  Branconnier  and  Jolene Fuller, wife and daughter, respectively, of
Rene  Branconnier.  The  Company  owes  accrued  rent for one year of $36,000 to
Brampton  Holdings  Ltd..

Under  the  SEC's  rules,  Mr.  Ren  Branconnier  and  Dr. Robert Jackman may be
considered  promoters  or  founders  of  Duro Enzymes Private and, following the
October 16, 2000 voluntary share exchange, the Company.  Dr. Robert Jackman owns
1,500,000  shares of the Company and during 2001 provided consulting services to
the  Company  through  FL  Tech  Inc.  for  which  $18,000 was accrued.  Mr. Ren
Branconnier  owns  750,000  shares  of  the  Company  and  during  2001 provided
consulting  services  to  the Company through 529473 B.C. Ltd. for which $24,000
was accrued.  Mr. Ren  Branconnier also owns 529473 B.C. Ltd.; accordingly he is
the  ultimate beneficiary of all agreements and arrangements between the Company
and  529473  B.C.  Ltd.  The agreements between 529473 B.C. Ltd. and the Company
and its subsidiaries were approved by the Company's Board of Directors.  FL Tech
a  company controlled by  Dr. Robert Jackman performs consulting work for 529473
B.C.  Ltd.;  Mr.  Dean  Branconnier is Mr. Ren  Branconnier's nephew; Ms. Jolene
Fuller,  a  director  at  the  time,  is  Mr.  Ren  Branconnier's  daughter.


ITEM  13.  EXHIBITS  AND  REPORTS  ON  FORM  8-K
------------------------------------------------

EXHIBITS

<TABLE>
<CAPTION>

Exhibit
Number     Description
<C>        <S>
3.1****    Amended and Restated Articles of Incorporation dated February 5, 2001
3.2****    Amended and Restated Bylaws dated January 8, 2001
  4.1**    Specimen Stock Certificate for Shares of Common Stock of the Company
   10.1    Lease Agreement dated December 12, 2001
10.2***    License and Distribution Agreement between 529473 B.C. Ltd. and Duro Enzyme Solutions Inc.
           (U.S.), as amended, dated September 22, 2000


                                       20
<PAGE>
  10.3*    Research and Development Services Agreement between 529473 B.C. Ltd. and Duro Enzyme
           Solutions Inc. (Canada), as amended, dated September 21, 2000
  10.4*    Research and Development Services Agreement between 529473 B.C. Ltd. and Duro Enzyme
           Solutions Inc. (U.S.), as amended, dated September 21, 2000
   16.1    Letter from BDO Dunwoody, Chartered Accountants, to the U.S. Securities and Exchange
           Commission
   16.2    Letter from Raber Mattuck, Chartered Accountants, to the U.S. Securities and Exchange
           Commission
   21.1    List of Subsidiaries
<FN>

*  Filed  on  November  20,  2000, as an exhibit to the Company's report on Form 10-QSB for the three
months  ended  September  30,  2000  and  incorporated  herein  by  reference
**  Filed on December 29, 2000, as an exhibit to the Company's transitional report on Form 10-KSB for
the  nine  months  ended  September  30,  2000  and  incorporated  herein  by  reference
***  Filed  on  February 14, 2001, as an exhibit to the Company's report on Form 10-QSB for the three
months  ended  December  31,  2000  and  incorporated  herein  by  reference.
**** Filed on May 15, 2001, as an exhibit to the Company's report on Form 10-QSB for the three months
ended  March  31,  2001,  and  incorporated  herein  by  reference.
</TABLE>



REPORTS  ON  FORM  8-K

No  reports  on  Form 8-K were filed by the Company during the fourth quarter of
the  fiscal  year  ended  September  30,  2001.


                                       21
<PAGE>
SIGNATURES
----------

In  accordance  with  Section  13  or  15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

DURO  ENZYME  PRODUCTS  INC.

                     By:  /s/  Robert L. Jackman
                        ------------------------
                     Robert  L.  Jackman
                     President,  Treasurer,  and  Director

                     Date:  December  21,  2001
                          ---------------------


In  accordance  with  the Exchange Act, this report has been signed below by the
following  persons  on behalf of the registrant and in the capacities and on the
dates  indicated.

                     By:  /s/  Robert L. Jackman         Date: December 21, 2001
                        ----------------------               -------------------
                        Robert L. Jackman
                        President, Treasurer and Director


                     By:  /s/  Dean  Branconnier         Date: December 21, 2001
                        --------------------                 -------------------
                        Dean  Branconnier
                        Vice  President  and  Director


                     By:  /s/  Chad  Burback             Date: December 21, 2001
                        ----------------                     -------------------
                        Chad  Burback
                        Secretary  and  Director


                                       22
<PAGE>
<TABLE>
<CAPTION>


                          INDEX TO FINANCIAL STATEMENTS


<S>                                                                           <C>
Independent Auditor's Report . . . . . . . . . . . . . . . . . . . . . . . .  F-1

Balance Sheet as at September 30, 2001 . . . . . . . . . . . . . . . . . . .  F-2

Statements of Operations for the year ended September 30, 2001, the
nine months ended September 30, 2000, the year ended December 31, 1999,
and the period from September 15, 1995 (inception) to September 30, 2001 . .  F-3

Statements of Stockholders Equity for the year ended September 30, 2001, the
nine months ended September 30, 2000, the year ended December 31, 1999,
and the period from September 15, 1995 (inception) to September 30, 2001 . .  F-4

Statement of Cash Flow for the year ended September 30, 2001, the
nine months ended September 30, 2000, the year ended December 31, 1999,
and the period from September 15, 1995 (inception) to September 30, 2001 . .  F-5

Notes to Financial Statements. . . . . . . . . . . . . . . . . . . . . . . .  F-6
</TABLE>


<PAGE>
To  the  Board  of  Directors  and  Shareholders
Duro  Enzyme  Products  Inc.
Langley,  British,  Columbia

                          INDEPENDENT AUDITOR'S REPORT

I  have  audited  the  balance sheet of Duro Enzyme Products Inc. (Formerly Home
Web,  Incorporated) (a development stage company) as of September 30, 2001, 2000
and  December  31,  1999 and the related statements of operations, stockholders'
equity  and  cash  flows  for  the year ended September 30, 2001, the nine month
period  ended  September 30, 2000 and the twelve month period ended December 31,
2000.  These  financial  statements  are  the  responsibility  of  the Company's
management.  My  responsibility  is  to  express  an  opinion on these financial
statements  based  on  my  audit.

I conducted my audit in accordance with generally accepted auditing standards of
the United States.  Those standards require that I plan and perform the audit to
obtain  reasonable  assurance about whether the financial statements are free of
material  misstatement.  An  audit includes examining, on a test basis, evidence
supporting  the  amounts  and  assessing  the  accounting  principles  used  and
significant  estimates  made  by  management,  as well as evaluating the overall
financial  statement  presentation.  I believe that my audit provides reasonable
basis  for  my  opinion.

The  accumulated  deficit  from  the  date of inception to September 30, 2001 is
$2,006,765.

In  my  opinion,  the  financial  statements  referred to in the first paragraph
present  fairly, in all material respects, the financial position of Duro Enzyme
Products Inc (Formerly Home Web, Incorporated) (A Development Stage Company), as
of  September 30, 2001, 2000 and December 31, 1999 the results of operations the
cash  flows  and  the cumulative results of operations and cumulative cash flows
for  the  year  then  ended  in  conformity  with  generally accepted accounting
principles  of  the  United  States.

The  accompanying  financial  statements have been prepared assuming the Company
will  continue  as  a  going  concern.  As discussed in Note 12 to the financial
statements,  the  Company  has  incurred net losses since inception, which raise
substantial  doubt  about  its  ability  to  continue  as  a going concern.  The
financial  statements  do  not include any adjustment that might result from the
outcome  of  this  uncertainty.


/s/  "Hawkins  Accounting"

DECEMBER  9,  2001


                                      F-1
<PAGE>
<TABLE>
<CAPTION>
                            DURO ENZYME PRODUCTS INC.
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)
                           CONSOLIDATED BALANCE SHEET
                 September 30, 2001, 2000 and December 31, 1999

ASSETS

                                                            2001          2000          1999
                                                        ------------  ------------  ------------
Current assets
<S>                                                     <C>           <C>           <C>
  Cash in bank                                          $     3,189   $         0   $         7
  Non-trade receivable                                           70         1,450         1,450
                                                        ------------  ------------  ------------
    Total current assets                                      3,259         1,450         1,457
Equipment
  Coolers and equipment                                                    40,308        40,308
  Office equipment                                                          9,841         9,841
                                                        ------------  ------------  ------------
                                                                  0        50,149        50,149
  Accumulated depreciation                                   (9,288)       (9,288)
                                                        ------------  ------------  ------------
    Total equipment                                               0        40,861        40,861
Other assets
  Trade name                                                               11,000        11,000
  Licenses (net)                                          2,250,000
                                                        ------------  ------------  ------------
    Total other assets                                    2,250,000        11,000        11,000
                                                        ------------  ------------  ------------
TOTAL ASSETS                                            $ 2,253,259   $    53,311   $    53,318
                                                        ============  ============  ============

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
  Accounts payable and fees                             $   153,383   $     1,426   $    17,655
  California Franchise Tax payable                                0             0         3,116
  Short term notes                                          107,833        25,962         2,825
                                                        ------------  ------------  ------------
    Total current liabilities                               261,216        27,388        23,596

Long term debt                                            2,627,740             0             0
                                                        ------------  ------------  ------------
TOTAL LIABILITIES                                         2,888,956        27,388        23,596
Shareholders' equity
  Preferred stock, 40,000,000 shares authorized $.001
    par value, 0 shares outstanding                               0             0             0
  Common stock, 160,000,000 authorized, $.001 par
  value, 32,876,400 outstanding                              27,507        27,507        27,507
  Paid in capital                                         1,347,493     1,347,493     1,347,493
  Deficit accumulated during development stage           (2,010,697)   (1,349,077)   (1,345,278)
                                                        ------------  ------------  ------------
    Total shareholders' equity                             (635,697)       25,923        29,722
                                                        ------------  ------------  ------------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY              $ 2,253,259   $    53,311   $    53,318
                                                        ============  ============  ============
</TABLE>


     The accompanying notes are an integral part of the financial statements


                                      F-2
<PAGE>
<TABLE>
<CAPTION>

                            DURO ENZYME PRODUCTS INC.
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)
                      CONSOLIDATED STATEMENT OF OPERATIONS
For the year ended September 30, 2001, the nine months ended September 30, 2000
                      and the year ended December 31, 1999

                                                                                Deficit
                                                                              Accumulated
                                                                                 During
                                                                               Development
                                         2001          2000          1999         Stage
                                     ------------  ------------  ------------  ------------
<S>                                  <C>           <C>           <C>           <C>
Sales                                $         0   $         0   $       528   $    18,887
Cost of Sales                                  0             0           523        15,091
                                     ------------  ------------  ------------  ------------
Gross Margin                                   0             0             5         3,796
Expenses
  Advertising                                                              7           856
  Amortization                           250,000                                   251,584
  Consulting and professional fees       195,406         2,929         5,500       209,531
  Equipment rental                                                                   2,339
  Depreciation                                                         4,003         9,288
  Licenses and taxes                                                     145           370
  Office help                                                          1,591        12,432
  Office supplies and postage              1,724            70           588         6,227
  Investor communication                   5,706                                     5,706
  Travel, meals and entertainment          8,567                          54        11,246
  Rent, utilities and telephone           36,000                         248        39,591
  Organization and start up costs                                     15,318        41,674
  Compensation due stock issuance                                                1,254,500
                                     ------------  ------------  ------------  ------------
    Total expenses                       497,403         2,999        27,454     1,845,344
                                     ------------  ------------  ------------  ------------
    (Loss) from operations              (497,403)       (2,999)      (27,449)   (1,841,548)
Other income (expense)
  Loss on write off assets               (53,311)                                  (53,361)
  Interest                              (134,354)                       (716)     (135,236)
  Recovery of accounts payable            27,380                                    27,380
  State tax expense                                       (800)       (1,600)       (4,000)
                                     ------------  ------------  ------------  ------------
    Total other expenses                (160,285)         -800        (2,316)     (165,217)
    Net loss                         $  (657,688)  $    (3,799)  $   (29,765)  $(2,006,765)
                                     ============  ============  ============  ============
Loss per share
  of common stock                    $     (0.02)  $   (0.0001)  $   (0.0010)  $     (0.06)
Weighted average of
  shares outstanding                  32,876,400    32,876,400    27,157,000    32,876,400
                                     ============  ============  ============  ============
</TABLE>


     The accompanying notes are an integral part of the financial statements


                                      F-3
<PAGE>
<TABLE>
<CAPTION>
                                   DURO ENZYME PRODUCTS INC.
                                      (FORMERLY HOME WEB)
                                 (A Development Stage Company)
                        CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY
         For the year ended September 30, 2001, for the nine months ended September 30,
                           1999 and the year ended December 31, 1999



                                              1999
                                          -----------

                                                                    Deficit
                                                                  Accumulated
                                   Common stock                     During
                             -----------------------   Paid in    Development
                               Shares       Amount     Capital       Stage        Total
                             -----------  ----------  ----------  ------------  ----------
<S>                          <C>          <C>         <C>         <C>           <C>
Balance,
   December 31, 1998         27,497,000   $  27,497   $1,347,003  $(1,315,513)  $  58,987
Common stock issued              10,000          10          490                      500
Net loss for the period
   ended September 30, 1999                                          (29,718)    (29,718)
                             -----------  ----------  ----------  ------------  ----------
                             27,507,000   $  27,507   $1,347,493  $(1,345,231)  $  29,769
                             ===========  ==========  ==========  ============  ==========



                                              2000
                                          -----------

Balance,
   December 31, 1999         27,507,000   $  27,507   $1,347,493  $(1,345,278)  $  29,722
February 23, 2000,
 forward stock split          5,369,400
Net loss for the period
   ended September 30, 2000                                            (3,799)     (3,799)
                             -----------  ----------  ----------  ------------  ----------
                             32,876,400   $  27,507   $1,347,493  $(1,349,077)  $  25,923
                             ===========  ==========  ==========  ============  ==========


                                              2001
                                          -----------
Balance
   September 30, 2000        32,876,400   $  27,507   $1,347,493  $(1,349,077)  $  25,923
Consolidation of subsidiary                                            (3,932)     (3,932)
Net loss for the year
   ended September 30, 2001                                          (657,688)   (657,688)
                             -----------  ----------  ----------  ------------  ----------
                             32,876,400   $  27,507   $1,347,493  $(2,010,697)  $(635,697)
                             ===========  ==========  ==========  ============  ==========
</TABLE>


     The accompanying notes are an integral part of the financial statements


                                      F-4
<PAGE>
<TABLE>
<CAPTION>
                            DURO ENZYME PRODUCTS INC.
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)
              CONSOLIDATED STATEMENT OF CASH FLOWS-INDIRECT METHOD
  For the year ended September 30, 2001, the nine months ended September 30, 2000
                      and the year ended December 31, 1999


                                                                                                Cash flows
                                                                                                Accumulated
                                                                                                  During
                                                                                                Development
                                                              2001         2000        1999        Stage
                                                           -----------  -----------  ---------  ------------
CASH FLOWS FROM OPERATING ACTIVITIES
<S>                                                        <C>          <C>          <C>        <C>
Net income (loss)                                          $ (657,688)  $   (3,799)  $(29,765)  $(2,006,765)
Adjustments to reconcile net income to net cash
  provided by operating activities
  Depreciation and amortization                               250,000                   4,003       259,288
  Stock issued for services                                                               500     1,254,500
  Expensing of organization costs                                                       2,376         2,366
  Increase in accounts payable                                153,383                  17,655       153,383
  Increase in accounts receivable                                 (70)                               (1,520)
  Recovery from accounts payable                              (27,388)                              (27,388)
  Loss on disposal of assets                                   53,311                                53,311
  Increase in accrued liabilities                                            3,792      5,141        27,888
                                                           -----------  -----------  ---------  ------------
NET CASH PROVIDED BY OPERATING
  ACTIVITIES                                                 (228,452)          (7)       (90)     (284,937)
INVESTING ACTIVITIES
  Increase in other assets                                                                           13,366
  Purchase of license                                       2,500,000                             2,500,000
  Purchase of equipment                                                                              50,149
                                                           -----------  -----------  ---------  ------------
NET CASH USED IN INVESTING ACTIVITIES                       2,500,000                             2,563,515
FINANCING ACTIVITIES
  Sale of common stock                                                                              120,000
  Retained earnings of subsidiary                              (3,932)                               (3,932)
  Long term debt                                            2,627,740                             2,627,740
  Short term notes                                            107,833                               107,833
                                                           -----------  -----------  ---------  ------------
NET CASH GENERATED FROM FINANCING ACTIVITIES                2,731,641                             2,851,641
INCREASE (DECREASE) IN CASH AND CASH
  EQUIVALENTS                                                   3,189           (7)       (90)        3,189
Cash and cash equivalents at the beginning of the period            0            7         97             0
                                                           -----------  -----------  ---------  ------------
CASH AND CASH EQUIVALENTS AT THE END OF
  THE PERIOD                                               $    3,189   $        0   $      7   $     3,189
                                                           ===========  ===========  =========  ============
</TABLE>


     The accompanying notes are an integral part of the financial statements


                                      F-5
<PAGE>
                            DURO ENZYME PRODUCTS INC.
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                 SEPTEMBER 30, 2001, 2000 AND DECEMBER 31, 1999


NOTE 1:     SIGNIFICANT ACCOUNTING POLICIES
            -------------------------------

Nature  of  business
--------------------
     Duro  Enzyme  Products Inc. (the Company) and its wholly owned subsidiaries
     currently through its licenses and research, manufacture unique, stable and
     natural  enzymes  and  specialty  end  products. The main activities of the
     business  was  moved  from  California  to  British  Columbia.


Name  change  and  accounting  year  change
-------------------------------------------
     The  Company  was  incorporated  under  the  laws of the State of Nevada on
     September  15,  1995.  The  Company was originally formed to sell wholesale
     gourmet  and specialty cheese on the Internet. On October 16, 2000 a merger
     was  completed with a private company (Duro Enzymes Products Inc.) in which
     shares  were  exchanged one for 28,800,000. The Company's name was formally
     changed  to  Duro  Enzyme  Products  Inc.  on February 5, 2001 at a special
     shareholders  meeting.

     The  accounting year was changed from a December 31 year-end to a September
     30  year-end.


Development  Stage  Company
---------------------------
     The  Company  is  a  development  stage company as defined in the Financial
     Accounting Standards Board No. 7. The Company is devoting substantially all
     of  its  present  efforts  in securing and establishing a new business, and
     although  planned principal operations have commenced, substantial revenues
     have  yet  to  be  realized.


Use  of  estimates
------------------
     The  preparation  of  the financial statements in conformity with generally
     accepted  accounting  principles of the United States require management to
     make  estimates and assumptions that affect the reported amounts of assets,
     liabilities  and  disclosures  of contingent liabilities at the date of the
     financial  statements  and  the  reported  amounts of revenues and expenses
     during  the reporting period. Accordingly, actual results could differ from
     these  estimates.


Principles  of  Consolidation
-----------------------------
     The  consolidated  financial statements include the accounts of Duro Enzyme
     Products  Inc.  and  its  wholly  owned  subsidiaries:
          Duro  Enzyme  Solutions  Inc., Nevada, USA
          Duro Enzyme Solutions Inc., British  Columbia  Canada

     All  material  transactions  have  been  eliminated.


                                      F-6
<PAGE>
                            DURO ENZYME PRODUCTS INC.
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                 SEPTEMBER 30, 2001, 2000 AND DECEMBER 31, 1999


NOTE  1:     SIGNIFICANT  ACCOUNTING  POLICIES  (CON'T)
             ------------------------------------------

     The  transaction was accounted for by the purchase method of accounting for
     business  combinations.

Cash  equivalents
-----------------
     For  the  purpose of the statement of cash flows, the company considers all
     highly  liquid  debt  instruments  purchased  with the original maturity of
     three  months  or  less  to  be  cash  equivalents.


Property  and  equipment
------------------------
     Property  and  equipment  are recorded at cost. Maintenance and repairs are
     expensed  as incurred; major renewals and betterments are capitalized. When
     items  of  property or equipment are sold or retired, the related costs and
     accumulated depreciation are removed from the accounts and any gain or loss
     is included in income. Depreciation is provided using the straight line and
     accelerated  methods  over  the useful lives provided by statute, including
     the election to expense the cost of property acquisitions in certain years.


Intangible  and  other  assets
------------------------------
     The  cost  of purchase of other assets is recorded at the purchase price of
     the  contract  and  amortized  over  its useful life not to exceed 10 years
     using  the straight-line method. Amortization cost for year ended September
     30,  2001  is  $250,000.

Income  Taxes
-------------
     Income  taxes  are provided for the tax effects of transactions reported in
     the  financial  statements and consist of taxes currently due plus deferred
     taxes  related primarily to differences between the recorded book basis and
     tax basis of assets and liabilities for financial and income tax reporting.
     The  deferred  tax  assets  and liabilities represent the future tax return
     consequences  of  those  differences,  which  will  either  be  taxable  or
     deductible  when  the  assets  and  liabilities  are  recovered  or settle.
     Deferred  taxes are also recognized for operating losses that are available
     to  offset  future  taxable  income  and  tax credits that are available to
     offset  future  federal  income  taxes.

NOTE  2:     LOSS  ON  DISPOSAL  OF  ASSETS
             ------------------------------

     Pursuant to the decision made by the board of directors to change the focus
     of  the  company  from the sale of gourmet food and specialty cheese on the
     Internet  to  the


                                      F-7
<PAGE>
                            DURO ENZYME PRODUCTS INC.
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                 SEPTEMBER 30, 2001, 2000 AND DECEMBER 31, 1999


NOTE  2:     LOSS  ON  DISPOSAL  OF  ASSETS  (CON'T)
             ---------------------------------------

     Research  and  development  of the license and manufacture of unique stable
     and natural enzymes and specialty end products the equipment and trade name
     that  was used to promote the sale of the gourmet food and specialty cheese
     was abandoned. The management of the Company made the decision to recognize
     the  loss  for  the  year  ending  September  30,  2001.

NOTE  3:     LICENSE
             -------

     During the year ended September 30, 2001 the Company through its subsidiary
     purchased  the  license  to  use  the exclusive technology both current and
     developed technology that the Company may develop from its own research for
     the term of the agreement. The purchase price of this license is $2,500,000
     US  dollars and was satisfied by a note payable. An additional fee of 2 1/2
     %  will  be  charged  on gross revenue will be due once sales commence. The
     $2,500,000 is being amortized over a 10-year period using the straight-line
     method.

NOTE  4:     RELATED  PARTY  TRANSACTION
             ---------------------------

     For the year ended September 30, 2001 the Company entered into transactions
     for  consulting  services  with 7 companies that are owned or controlled by
     shareholders  or creditors of the Company. At September 30, 2001 the amount
     outstanding  and  unpaid  is  $120,000.

     During  the  year  ended  September  30,  2001  the  Company entered into a
     consulting agreement with one of its major creditors. This agreement is for
     research  and related services plus out of pocket expenses. The amount owed
     to  this  related  party  as  of  September  30,  2001  is  $107,833, which
     represents  the  short-term  loans advanced to the Company. The sale of the
     license  and  the  corresponding  long-term  debt  of $2,627,740 is due the
     company  that  this  related party controls. The Company also leases office
     space  from this creditor and owes accrued rent at year ended September 30,
     2001  of  $36,000.

     During  the period ending September 30, 2000 an affiliated company advanced
     the Company $20,908. This money was used to pay off the accounts payable as
     of June 30, 2000. For the period ended December 31, 1999 the Company paid a
     total  of  $5,400  in  rent  and  consulting fees per an agreement with the
     affiliate.


                                      F-8
<PAGE>
                            DURO ENZYME PRODUCTS INC.
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                 SEPTEMBER 30, 2001, 2000 AND DECEMBER 31, 1999


NOTE  5:     INCOME  TAXES
             -------------

     The  benefit  for  income  taxes from operations consisted of the following
     components:  current  tax  benefit  of  $234,000  for  September  30,  2001
     resulting from a net loss before income taxes, and deferred tax expenses of
     $  234,000  resulting  from  a  valuation  allowance  recorded  against the
     deferred  tax asset resulting from net operating losses. Net operating loss
     carryforward  will  expire  in  2013.

     The  valuation  allowance  will  be  evaluated  at  the  end  of each year,
     considering  positive and negative evidence about whether the asset will be
     realized.  At  the time, the allowance will either be increased or reduced;
     reduction  would  result  in  the  complete elimination of the allowance if
     positive  evidence indicates that the value of the deferred tax asset is no
     longer  required.

     No  provision  is  being  made  for  state  income  tax for the year ending
     September  30,  2001  since  all  operations were moved to Canada. In prior
     years the operations were in California and California Franchise taxes were
     applicable.


NOTE  6:     COMMON  STOCK
             -------------

     The  only  transaction  during  the  period of December 31, 1999 was 10,000
     shares  of  stock  issued  to  the  corporate counsel in exchange for legal
     services  to the corporation. An expense for legal services was recorded in
     this  exchange  for  the  stock.

     On  February  10,  2000  the board of directors voted a 1.2:1 forward stock
     split  as  of  the  record  date  of  February  23,  2000.


NOTE  7:     DEPRECIATION
             ------------

     For  the  year  ended  December  31,  1999  was  $4,003.

NOTE  8:     NOTES  PAYABLE
             --------------

     Note  payable  annual interest of 5% per annum. Note is tied to purchase of
     the license agreement. Payment terms are tied to the commencing of sales by
     the Company. Interest accrues until such time as six months from first date
     of sales. At such time, principal plus accrued interest will be repaid over
     five  years.


                                      F-9
<PAGE>
                            DURO ENZYME PRODUCTS INC.
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                 SEPTEMBER 30, 2001, 2000 AND DECEMBER 31, 1999


NOTE  9:     EARNINGS  PER  SHARE
             --------------------

     Basic  earnings  per  share  are computed by dividing earnings available to
     common  stockholders  by  the  weighted  average  number  of  common shares
     outstanding during the period. Diluted earnings per share reflect per share
     amounts  that  would have resulted if resulted if dilutive potential common
     stock  had been converted to common stock. The following reconciles amounts
     reported  in  the  financial  statements.


                                              For  the  Year  Ended  1999
                                     -------------------------------------------
                                        Income           Shares       Per-Share
                                     (Numerator)     (Denominator)      Amount
                                     -----------     ---------------------------
Income  from  continuing  operations
 available  to  common  stockholders
 basic  earnings  per  share          $(29,765)         27,157,000      $(.001)
                                                                       =========


                                         For  the  Nine  Months  Ended  2000
                                     -------------------------------------------
                                       Income           Shares         Per-Share
                                     (Numerator)     (Denominator)       Amount
                                     -----------     ---------------------------
Income  from  continuing  operations
 available  to  common  stockholders
 basic  earnings  per  share         $  (3,799)         32,876,400     $(.0001)
                                                                       =========


                                             For  the  Year  Ended  2001
                                     -------------------------------------------
                                       Income           Shares        Per-Share
                                     (Numerator)     (Denominator)      Amount
                                     -----------     ---------------------------
Income  from  continuing  operations
 available  to  common  stockholders
 basic  earnings  per  share          $(657,688)       32,876,400      $(.02)
                                                                       =========

NOTE  10:     LEASES
              ------

     The  Company  leases  office  space  on a year-to-year basis. This lease is
     recorded as an operating lease and the amounts paid are charged to expense.
     Total  charged  to  rent  expense  under  this lease during the fiscal year
     ending April 30, 2001 was $36,000. It is expected in the ordinary course of
     business  that  the  company  will renew its lease at its present location.


                                      F-10
<PAGE>
                            DURO ENZYME PRODUCTS INC.
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                 SEPTEMBER 30, 2001, 2000 AND DECEMBER 31, 1999


NOTE  11:     MERGER
              ------

     On  October  16,  2000  the  Company  conducted  a voluntary share exchange
     whereby  it  offered  up  to  28,800,000  shares of its common stock to the
     shareholders  of  the  original  Duro Enzymes Products Inc. ("Original Duro
     Enzyme")  in  exchange  for  all  of  the  issued and outstanding shares of
     Original  Duro  Enzyme.  The  effect  of the share exchange was to transfer
     control  of  the  Company  to the shareholders of Original Duro Enzyme. The
     majority  of  shares  of the Company are now held by former shareholders of
     Original Duro Enzyme. The Company effectively took control of all assets of
     Original  Duro  Enzyme,  including  its  subsidiaries, by becoming its sole
     shareholder.

NOTE  12:     GOING  CONCERN
              --------------

     As  of  September  30,  2001,  the  Company  had  net losses from operating
     activities,  which raise substantial doubt about its ability to continue as
     a  going  concern.

     The  Company  hopes  to  raise  funds  through the sale of its stock on the
     market.  It  further  hopes to continue its research and development of its
     products  and  to  begin  production  in  the  next  fiscal  year.

     The  Company's  ability  to continue as a going concern is dependent upon a
     successful  public offering and ultimately achieving profitable operations.
     There is no assurance that the Company will be successful in its efforts to
     raise  additional  proceeds or achieve profitable operations. The financial
     statements  do  not  include  any  adjustments  that  might result from the
     outcome  of  this  uncertainty.



                                      F-11
<PAGE>
                                  EXHIBIT INDEX

<TABLE>
<CAPTION>

EXHIBIT
NUMBER   DESCRIPTION
<C>      <S>

3.1****    Amended and Restated Articles of Incorporation dated February 5, 2001

3.2****    Amended and Restated Bylaws dated January 8, 2001

  4.1**    Specimen Stock Certificate for Shares of Common Stock of the Company

   10.1    Lease Agreement dated December 12, 2001

10.2***    License and Distribution Agreement between 529473 B.C. Ltd. and Duro Enzyme Solutions Inc.
           (U.S.), as amended, dated September 22, 2000

  10.3*    Research and Development Services Agreement between 529473 B.C. Ltd. and Duro Enzyme
           Solutions Inc. (Canada), as amended, dated September 21, 2000

  10.4*    Research and Development Services Agreement between 529473 B.C. Ltd. and Duro Enzyme
           Solutions Inc. (U.S.), as amended, dated September 21, 2000

   16.1    Letter from BDO Dunwoody, Chartered Accountants, to the U.S. Securities and Exchange
           Commission

   16.2    Letter from Raber Mattuck, Chartered Accountants, to the U.S. Securities and Exchange
           Commission

   21.1    List of Subsidiaries
<FN>

*  Filed  on  November  20,  2000, as an exhibit to the Company's report on Form 10-QSB for the three
months  ended  September  30,  2000  and  incorporated  herein  by  reference
**  Filed on December 29, 2000, as an exhibit to the Company's transitional report on Form 10-KSB for
the  nine  months  ended  September  30,  2000  and  incorporated  herein  by  reference
***  Filed  on  February 14, 2001, as an exhibit to the Company's report on Form 10-QSB for the three
months  ended  December  31,  2000  and  incorporated  herein  by  reference.
**** Filed on May 15, 2001, as an exhibit to the Company's report on Form 10-QSB for the three months
ended  March  31,  2001,  and  incorporated  herein  by  reference.
</TABLE>


<PAGE>